var title_f39_8_40064="Construction of a loop colostomy - abdominal wall";
var content_f39_8_40064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Construction of a loop colostomy - abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures depict the loop of colon being brought onto the abdominal wall. A plastic rod or red rubber catheter prevents retraction of the bowel into the abdominal cavity.",
"    <br>",
"     Figure A shows a small opening made in the mesentery with a finger, just large enough to pass the rod or catheter.",
"     <br>",
"      Figure B shows the rod in place.",
"      <br>",
"       Figure C shows a tube catheter attached to each end of the rod.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40064=[""].join("\n");
var outline_f39_8_40064=null;
var title_f39_8_40065="Phonocardiogram bicusid AS at 2nd R ICS";
var content_f39_8_40065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1287px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77091/asb2rics_conv.mp4?title=Phonocardiogram+bicusid+AS+at+2nd+R+ICS\" style=\"width:584px;height:390px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Carotid artery pulse tracing and phonocardiogram of aortic stenosis with bicuspid valve at the 2nd right intercostal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carotid artery pulse tracing and phonocardiogram of aortic stenosis as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by an ejection click (opening of the stenotic aortic valve) and a mid systolic ejection murmur of aortic stenosis. A single S2 results from delayed closure of the aortic valve which occurs simultaneously with pulmonic valve closure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40065=[""].join("\n");
var outline_f39_8_40065=null;
var title_f39_8_40066="Patient information: Acromegaly (The Basics)";
var content_f39_8_40066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16728\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/19/18739\">",
"         Pituitary gland",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/36/44608\">",
"          Surgery to remove a pituitary tumor",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/5/9298\">",
"         Patient information: Colon polyps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/28/7619\">",
"         Patient information: Pituitary adenoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/27/43443\">",
"         Patient information: Acromegaly (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acromegaly (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acromegaly-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13656992\">",
"      <span class=\"h1\">",
"       What is acromegaly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acromegaly is a disease that makes some parts of the body grow bigger than normal. This happens over a long period of time, often years.",
"     </p>",
"     <p>",
"      Acromegaly is usually caused by a non-cancerous tumor in the pituitary gland. The pituitary gland is located at the base of the brain (",
"      <a class=\"graphic graphic_figure graphicRef63094 \" href=\"mobipreview.htm?18/19/18739\">",
"       figure 1",
"      </a>",
"      ). It makes many hormones, including one called &ldquo;growth hormone,&rdquo; which the body needs to grow. A tumor in the pituitary gland can cause it to release too much growth hormone.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657007\">",
"      <span class=\"h1\">",
"       What are the symptoms of acromegaly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms involve too much growth in some parts of the body, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Face and head &ndash; The nose, lips, ears, and forehead get larger. The tongue and lower jaw also grow, and the spaces between the teeth get wider.",
"       </li>",
"       <li>",
"        Throat &ndash; The tissue inside the throat and around the voice box can grow bigger than normal. This can cause a hoarse voice or trouble breathing during sleep.",
"       </li>",
"       <li>",
"        Hands and feet &ndash; The hands and feet become bigger and swollen. People with acromegaly usually notice that their rings and shoes become tighter. Some people develop &ldquo;carpal tunnel syndrome,&rdquo; which is a condition that causes pain or tingling in the hands and fingers.",
"       </li>",
"       <li>",
"        Skin &ndash; Skin might become thicker. Some people also get small growths of extra skin (called &ldquo;skin tags&rdquo;).",
"       </li>",
"       <li>",
"        Bones &ndash; The ends of the bones can grow too much. This can damage the cartilage (the rubbery material that keeps bones from scraping against each other), and eventually lead to arthritis.",
"       </li>",
"       <li>",
"        Tumors &ndash; People with acromegaly have a higher risk of getting non-cancerous tumors. These can include fibroids (growths in the uterus, or womb) and colon polyps (small growths in the intestine).",
"       </li>",
"       <li>",
"        Heart &ndash; The heart muscle can grow bigger than normal, which can make it hard for the heart to work well. People with acromegaly are also more likely to have high blood pressure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a tumor on the pituitary gland gets too big, it can press on the nerves that lead to the eyes. This sometimes causes vision problems.",
"     </p>",
"     <p>",
"      Acromegaly also increases the chance that a person will get diabetes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657021\">",
"      <span class=\"h1\">",
"       Is there a test for acromegaly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Usually, a doctor or nurse suspects acromegaly based on a person&rsquo;s appearance. He or she can do a blood test to check if there is too much growth hormone in the blood.",
"     </p>",
"     <p>",
"      If a blood test shows the person has too much growth hormone, the doctor or nurse might order an MRI. An MRI is an imaging test that creates pictures of the inside of your body. It can show if there is a tumor in the pituitary gland.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657036\">",
"      <span class=\"h1\">",
"       How is acromegaly treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery - In some cases, doctors can do surgery to remove the tumor in the pituitary gland. An experienced surgeon makes a small cut in the nose and then uses a special tool to take the tumor out (",
"        <a class=\"graphic graphic_figure graphicRef75464 \" href=\"mobipreview.htm?43/36/44608\">",
"         figure 2",
"        </a>",
"        ). If the surgeon can completely remove it, the amount of growth hormone in the body will return to normal within hours. Some symptoms take a few months to get better.",
"       </li>",
"       <li>",
"        Medicines - Some people with acromegaly need to take medicines. You might need medicine if you have a pituitary tumor that is too big for doctors to remove it completely with surgery. There are 3 kinds of medicine doctors use to treat acromegaly:",
"       </li>",
"       <li>",
"        Injections (shots) that stop the tumor from releasing hormones &ndash; There is one kind that you use 3 times a day, and another kind that you use once every 4 weeks.",
"       </li>",
"       <li>",
"        Pills that stop the tumor from releasing hormones &ndash; These usually don&rsquo;t work as well as the medicines you can get through injections. But they might be easier to take.",
"       </li>",
"       <li>",
"        Medicine that blocks the effects of growth hormone &ndash; You take this once a day as an injection.",
"       </li>",
"       <li>",
"        Radiation &ndash; Sometimes doctors treat pituitary tumors with radiation. Radiation uses high doses of X-rays to destroy the tumor.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these treatments can have side effects. Your doctor can talk to you about which treatments are best for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657051\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women with acromegaly are able to have normal pregnancies. Before trying to get pregnant, ask your doctors about which medicines are safe to take during pregnancy. You will also need to see your endocrinologist (the doctor who treats your acromegaly) regularly while you are pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657066\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can successfully treat most people with acromegaly. You will need to see your doctor regularly to make sure that your treatments are working, and make changes if needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13657081\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9298?source=see_link\">",
"       Patient information: Colon polyps (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/28/7619?source=see_link\">",
"       Patient information: Pituitary adenoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/27/43443?source=see_link\">",
"       Patient information: Acromegaly (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/8/40066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16728 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40066=[""].join("\n");
var outline_f39_8_40066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13656992\">",
"      What is acromegaly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657007\">",
"      What are the symptoms of acromegaly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657021\">",
"      Is there a test for acromegaly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657036\">",
"      How is acromegaly treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657051\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657066\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13657081\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/19/18739\">",
"      Pituitary gland",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/36/44608\">",
"       Surgery to remove a pituitary tumor",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9298?source=related_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/28/7619?source=related_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40067="Onychorrhexis";
var content_f39_8_40067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Longitudinal nail grooves with distal splits (onychorrhexis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40067=[""].join("\n");
var outline_f39_8_40067=null;
var title_f39_8_40068="Chorionic villi1";
var content_f39_8_40068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78715%7EOBGYN%2F61424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78715%7EOBGYN%2F61424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorionic villi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One method of distinguishing placenta from organized clot is to rinse with water and then float the tissue in a dish of water, preferably with a good light source underneath. Villi have a frond-like appearance, which has been described as similar to seaweed floating in the ocean",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Errol R Norwitz, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorionic villi2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Errol R Norwitz, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40068=[""].join("\n");
var outline_f39_8_40068=null;
var title_f39_8_40069="Doxepin (systemic): Patient drug information";
var content_f39_8_40069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxepin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/32/44551?source=see_link\">",
"     see \"Doxepin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=see_link\">",
"     see \"Doxepin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10570484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Silenor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Doxepin&reg;;",
"     </li>",
"     <li>",
"      Doxepine;",
"     </li>",
"     <li>",
"      Novo-Doxepin;",
"     </li>",
"     <li>",
"      Silenor&reg;;",
"     </li>",
"     <li>",
"      Sinequan&reg;;",
"     </li>",
"     <li>",
"      Zonalon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease long-term pain problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxepin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2913779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine or glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (concentrate) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2913799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Silenor&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11663 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40069=[""].join("\n");
var outline_f39_8_40069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10570484\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030998\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031000\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030999\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031004\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031005\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031007\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031002\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031003\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031008\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031009\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/32/44551?source=related_link\">",
"      Doxepin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/8/14470?source=related_link\">",
"      Doxepin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40070="Latex allergy: Management";
var content_f39_8_40070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Latex allergy: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Robert G Hamilton, PhD, DABMLI, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40070/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/8/40070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural rubber latex allergy is caused by sensitization to proteins in the sap-like fluid (latex) from the commercial rubber tree, Hevea brasiliensis (Hev b). Most patients are sensitized through exposure to latex gloves in a medical or occupational setting.",
"   </p>",
"   <p>",
"    The mainstay of management of latex allergy is avoidance of latex products. Several therapies are under investigation, including immunotherapy and anti-IgE therapy.",
"   </p>",
"   <p>",
"    The management of latex allergy, including avoidance measures and experimental therapies will be reviewed here. An overview of latex processing and latex allergens, and review of the epidemiology, clinical manifestations, and diagnosis of latex allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"     \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latex allergy can involve delayed or immediate-type reactions. Individuals with delayed hypersensitivity, manifested as a contact dermatitis, are at increased risk for developing IgE-mediated reactions. Thus, all individuals with latex sensitivity should be managed similarly.",
"   </p>",
"   <p>",
"    There are four possible strategies for preventing or managing allergic symptoms once an individual is diagnosed with latex allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance",
"     </li>",
"     <li>",
"      Pharmacotherapy",
"     </li>",
"     <li>",
"      Immunotherapy",
"     </li>",
"     <li>",
"      Anti-IgE therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, the most effective and least expensive method is avoidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Institutional avoidance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Individual avoidance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of acute and chronic allergic symptoms with pharmacotherapy is possible. However, prevention of reactions is preferred. Unfortunately, preventive pharmacotherapy is rarely effective.",
"   </p>",
"   <p>",
"    The use of immunotherapy is limited, due to the high frequency of adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Immunotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Anti-IgE therapy is under investigation for use in patients with IgE-mediated latex allergy as an off-label indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Anti-IgE is sometimes used together with an immunotherapy regimen. It is costly and patients must have the appropriate body weight and total serum IgE level to be a candidate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSTITUTIONAL AVOIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creation of a latex safe environment involves recognizing the importance of controlling latex exposure for allergic patients, convening a latex committee, and establishing an institutional program to eliminate exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ]. A multi-disciplinary latex advisory committee should be composed of local experts with knowledge in legal matters, purchasing, occupational safety, allergy, and glove use, including surgery, medicine, and anesthesiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/1,9,12,13\">",
"     1,9,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishment of latex safe environmental policies involves replacing Hevea latex containing products with non-Hevea based synthetic products, if possible, or powder-free latex products. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Hevea latex alternatives'",
"    </a>",
"    below.) Powder-free natural rubber latex products undergo a final chlorination step that removes a large percentage of Hevea allergenic protein.",
"   </p>",
"   <p>",
"    The primary source of Hevea latex exposure in medical institutions is the medical",
"    <span class=\"nowrap\">",
"     examination/surgical",
"    </span>",
"    glove (both non-sterile and sterile gloves) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/3,14,15\">",
"     3,14,15",
"    </a>",
"    ]. Some institutions have globally converted only their examination gloves to synthetic alternatives, while others have transitioned all gloves to non-Hevea alternatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/4,9,11,13,16\">",
"     4,9,11,13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing a latex safe environment in an institution leads to a decrease in latex-induced symptoms and reported employee and patient sensitivity. However, latex-specific IgE antibody can remain detectable in the skin and blood of individuals who avoid latex exposure for at least five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/3,4,11,17-19\">",
"     3,4,11,17-19",
"    </a>",
"    ]. Thus, continued avoidance is recommended. Yearly serologic evaluation should be considered to monitor for possible resolution of sensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDIVIDUAL AVOIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals with latex allergy, whether or not they come in contact with potentially contaminated body fluids, should use only non-Hevea medical gloves. In addition to gloves, there are as many as 40,000 consumer products in home and",
"    <span class=\"nowrap\">",
"     medical/dental",
"    </span>",
"    environments that may contain latex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Examples are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef59584 \" href=\"mobipreview.htm?38/5/39004\">",
"     table 1",
"    </a>",
"    ). Latex-containing forms of these products should be avoided as well. In the United States, Hevea latex-containing medical devices must be labeled \"containing natural rubber latex\" with a medical alert black box warning. Unfortunately, to date there is no requirement for companies to label rubber products with their latex protein content. Consumer products do not have the same stringent labeling requirement, however, many are labeled as containing latex.",
"   </p>",
"   <p>",
"    For high-risk healthcare workers and sensitized patients, latex avoidance is critically important to reduce current symptoms and further sensitization. Institutions that have an employee with latex allergy must adhere to strict policies. At a minimum, such policies permit only the use of powder-free latex products for all employees and latex-free products for the sensitized individual. It is not acceptable to only give the worker with latex allergy special latex-free gloves, since their environment can endanger them if a coworker inadvertently uses a Hevea allergen-rich glove. Use of powder-free latex gloves by coworkers decreases, but does not eliminate, symptoms in health care workers with latex allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEVEA ALLERGEN CONTENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring the level of Hevea allergens in various products and occupational settings can document the risk for Hevea allergen exposure. This determination can be used to assess the necessity for an institutional transition to non-Hevea latex containing products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/9,12,13,16,17,23\">",
"     9,12,13,16,17,23",
"    </a>",
"    ]. It is not known what the threshold limits are for latex allergens. One earlier study using older assay methods suggested a latex aeroallergen threshold of 0.5",
"    <span class=\"nowrap\">",
"     nanograms/cubic",
"    </span>",
"    meter of air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/24\">",
"     24",
"    </a>",
"    ]. Similar threshold determinations have not been performed using the newer immunoenzymetric assays.",
"   </p>",
"   <p>",
"    The American Society for Testing Materials (ASTM) has established three standardized assays for Hevea product and environmental monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total protein - The modified Lowry test (ASTM D5712) was the first assay developed to monitor total Hevea protein in product extracts or environmental specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. This assay has limited analytic sensitivity. Thus, it is only able to quantify high levels of total extractable protein from Hevea rubber products. Moreover, it does not discriminate between allergenic and non-allergenic Hevea proteins.",
"     </li>",
"     <li>",
"      Hevea antigens - Hevea proteins that elicit an antibody response can be detected with the ASTM D6499 antigen ELISA (enzyme linked immunosorbent assay) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/25,27\">",
"       25,27",
"      </a>",
"      ]. This assay does not distinguish between latex allergens (IgE inducing) and non-allergenic antigens (non-IgE inducing), and therefore it only provides an indirect measure of the allergenic potential of a product or environment.",
"     </li>",
"     <li>",
"      Hevea allergens - Of the 14 known Hevea allergens, Hev b 1, 3, 5, and 6.02 have been identified as the principal \"indicator\" allergens for monitoring products and environments (",
"      <a class=\"graphic graphic_table graphicRef71927 \" href=\"mobipreview.htm?10/2/10285\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link&amp;anchor=H3#H3\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Hevea indicator allergens'",
"      </a>",
"      .) Two-site monoclonal antibody-based IEMAs (immunoenzymetric assays) (ASTM D7427-08) are established as standard methods that provide quantitative estimates of the indicator allergens in product extracts and environmental samples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The sum of the Hev b 1, 3, 5, and 6.02 content in physiologic extracts reflects the allergenic potential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/32\">",
"       32",
"      </a>",
"      ]. Quantification of Hev b 1 and Hevamine alone is insufficient to effectively assess rubber product allergen potency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other assays for Hevea allergens such as the human IgE anti-latex based competitive inhibition assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/19\">",
"     19",
"    </a>",
"    ] remain research tools in selected laboratories, due to their requirement for large amounts of human IgE anti-latex containing serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEVEA LATEX ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic elastomers and a non-Hevea rubber (Yulex) have been developed for use as alternatives in the manufacturing of commercial \"rubber-like\" products:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common synthetic elastomers include butyl rubber, a completely petroleum-based product with no allergenic protein, polymers of 2-chlorobutadiene (neoprene), and copolymers of butadiene and acrylonitrile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/33\">",
"       33",
"      </a>",
"      ]. The predominant non-sterile, non-latex examination gloves used in medical institutions today are made of nitrile, neoprene, vinyl, or synthetic polyisoprene rubber that is extracted from oil. Their color (white, blue, purple, or green) is arbitrary and does not reflect the type of material in the glove. Different glove materials vary in terms of their ability to be sterilized and still maintain their barrier properties.",
"     </li>",
"     <li>",
"      A non-Hevea source of natural rubber is the Guayule plant (Yulex) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. The raw material extracted from the shrub has an ultra-low protein content. The proteins that are present display no apparent in vitro or in vivo cross-reactivity with Hevea latex allergens. Thus, Yulex-based rubber products should pose no risk to individuals who are allergic to Hevea latex. In the United States, Yulex-based products are cleared by the Food and Drug Administration (FDA), but are not yet commercially available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH IN THE WORKPLACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach for managing a worker with suspected natural rubber latex (NRL) allergy begins with confirmation of the diagnosis of latex allergy using validated diagnostic methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/1,12,16\">",
"     1,12,16",
"    </a>",
"    ]. Confirmation of latex sensitization can justify efforts put forth for cessation of further natural rubber latex exposure in the patient's workplace.",
"   </p>",
"   <p>",
"    One must then document that impairment and disability results from latex exposure in the workplace. The employer then needs to be educated about the patient's diagnosis and their responsibility to provide effective interventions to create a latex safe environment. If the patient cannot be effectively accommodated, workers' compensation benefits and rehabilitation may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT BY THE INDIVIDUAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several measures for the latex-allergic individual are recommended to prevent and manage allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/20,36\">",
"     20,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A medical alert bracelet indicating latex allergy should be worn.",
"     </li>",
"     <li>",
"      Self-injectable epinephrine should be prescribed for all individuals with a clinical history of systemic reactions to latex. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=see_link\">",
"       \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-latex gloves should be carried.",
"     </li>",
"     <li>",
"      Patients should report their allergy prior to any medical, dental, gynecologic, or surgical procedure and request a latex-safe environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link&amp;anchor=H16#H16\">",
"       \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\", section on 'Latex'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of immunotherapy (IT) for the treatment of IgE-mediated latex allergy is limited by the frequency and severity of reactions to IT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small randomized trials were performed with conventional subcutaneous immunotherapy (SCIT) using crude latex extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Efficacy was variable. One trial demonstrated decreased symptoms of urticaria and rhinoconjunctivitis, but not asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/38\">",
"     38",
"    </a>",
"    ], whereas another did show reduced airway hyperreactivity to latex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/39\">",
"     39",
"    </a>",
"    ]. A third trial failed to demonstrate any difference in medication use or symptom scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/40\">",
"     40",
"    </a>",
"    ]. A high frequency of adverse events, including systemic reactions, was reported in all studies. In one trial, adverse events occurred with similar frequency in both the induction and maintenance phases of the regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest that the frequency and severity of adverse events is lower with sublingual immunotherapy (SLIT) compared with SCIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. However, results vary and anaphylaxis has been reported with SLIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Novel IT approaches are under investigation to decrease the risk of severe adverse reactions (allergenicity) and yet maintain or improve efficacy (immunogenicity). These approaches include recombinant allergens, T cell epitope-based peptides, and adjuvants that are conjugated to or coadministered with the allergen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40070/abstract/20,49\">",
"     20,49",
"    </a>",
"    ]. These therapies are still in the experimental stages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once latex allergy is diagnosed, avoidance should be instituted as the primary method of management. Pharmacotherapy, immunotherapy, and anti-IgE therapy are not substitutes for effective avoidance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General management strategies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Institutional policy changes in the use of Hevea products are needed to reduce occupational and patient exposures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Institutional avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of non-latex containing gloves is recommended for individuals with latex allergy who use protective gloves. In addition, use of low-powder latex gloves by coworkers decreases exposure and sufficiently decreases symptoms in the latex allergic individual in most cases. However, use of non-latex gloves by all is preferred. Other latex-containing products should also be avoided. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Individual avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standardized assay methods for the quantification of antigenic and allergenic Hevea proteins facilitate the identification of highly allergenic Hevea-containing products and occupational environments. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hevea allergen content'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synthetics and Yulex, a non-Hevea rubber, are alternative products that are considered safe for use in Hevea sensitized individuals. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hevea latex alternatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional measures recommended for patients with latex allergy include having auto-injectable epinephrine available, carrying non-latex gloves, wearing a medical alert bracelet, and requesting a latex-safe environment for procedures or employment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management by the individual'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/1\">",
"      Bernstein DI. Management of natural rubber latex allergy. J Allergy Clin Immunol 2002; 110:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/2\">",
"      Sutherland MF, Suphioglu C, Rolland JM, O'Hehir RE. Latex allergy: towards immunotherapy for health care workers. Clin Exp Allergy 2002; 32:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/3\">",
"      Kelly KJ, Wang ML, Klancnik M, Petsonk EL. Prevention of IgE Sensitization to Latex in Health Care Workers After Reduction of Antigen Exposures. J Occup Environ Med 2011; 53:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/4\">",
"      Blumchen K, Bayer P, Buck D, et al. Effects of latex avoidance on latex sensitization, atopy and allergic diseases in patients with spina bifida. Allergy 2010; 65:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/5\">",
"      Rolland JM, O'Hehir RE. Latex allergy: a model for therapy. Clin Exp Allergy 2008; 38:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/6\">",
"      Nucera E, Schiavino D, Sabato V, et al. Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush build-up phase. Curr Med Res Opin 2008; 24:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/7\">",
"      Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/8\">",
"      Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/9\">",
"      Cusick C. A latex-safe environment is in everyone's best interest. Mater Manag Health Care 2007; 16:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/10\">",
"      SGNA Practice Committee. Guideline for preventing sensitivity and allergic reactions to natural rubber latex in the workplace. Gastroenterol Nurs 2008; 31:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/11\">",
"      Accetta D, Kelly KJ. Recognition and management of the latex-allergic patient in the ambulatory plastic surgical suite. Aesthet Surg J 2011; 31:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/12\">",
"      Bernstein DI, Karnani R, Biagini RE, et al. Clinical and occupational outcomes in health care workers with natural rubber latex allergy. Ann Allergy Asthma Immunol 2003; 90:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/13\">",
"      Cremer R, Kleine-Diepenbruck U, Hering F, Holschneider AM. Reduction of latex sensitisation in spina bifida patients by a primary prophylaxis programme (five years experience). Eur J Pediatr Surg 2002; 12 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/14\">",
"      Yunginger JW, Jones RT, Fransway AF, et al. Extractable latex allergens and proteins in disposable medical gloves and other rubber products. J Allergy Clin Immunol 1994; 93:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/15\">",
"      Kujala V, Alenius H, Palosuo T, et al. Extractable latex allergens in airborne glove powder and in cut glove pieces. Clin Exp Allergy 2002; 32:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/16\">",
"      Brown RH, Hamilton RG, McAllister MA, Johns Hopkins Latex Task Force. How health care organizations can establish and conduct a program for a latex-safe environment. Jt Comm J Qual Saf 2003; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/17\">",
"      Hamilton RG, Brown RH. Impact of personal avoidance practices on health care workers sensitized to natural rubber latex. J Allergy Clin Immunol 2000; 105:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/18\">",
"      Bernstein DI, Biagini RE, Karnani R, et al. In vivo sensitization to purified Hevea brasiliensis proteins in health care workers sensitized to natural rubber latex. J Allergy Clin Immunol 2003; 111:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/19\">",
"      Smith AM, Amin HS, Biagini RE, et al. Percutaneous reactivity to natural rubber latex proteins persists in health-care workers following avoidance of natural rubber latex. Clin Exp Allergy 2007; 37:1349.",
"     </a>",
"    </li>",
"    <li>",
"     Sussman, G, Gold, M. Guidelines for the management of latex allergies and safe latex use in health care facilities. Am College of Allergy Asthma and Immunology 1996. www.acaai.org/public/physicians/latex.htm (Accessed on January 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/21\">",
"      Kostyal D, Horton K, Beezhold D, et al. Latex as a significant source of Hevea brasiliensis allergen exposure. Ann Allergy Asthma Immunol 2009; 103:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/22\">",
"      Nienhaus A, Kromark K, Raulf-Heimsoth M, et al. Outcome of occupational latex allergy--work ability and quality of life. PLoS One 2008; 3:e3459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/23\">",
"      Lee MF, Wang NM, Han JL, et al. Estimating allergenicity of latex gloves using Hev b 1 and hevamine. J Investig Allergol Clin Immunol 2010; 20:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/24\">",
"      Baur X. I are we closer to developing threshold limit values for allergens in the workplace? Ann Allergy Asthma Immunol 2003; 90:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/25\">",
"      Beezhold DH, Kostyal DA, Tomazic-Jezic VJ. Measurement of latex proteins and assessment of latex protein exposure. Methods 2002; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     ASTM D5712-05E1: Standard test method for analysis of aqueous extractable protein in natural rubber and its products using the modified Lowry method. American Society for Testing Materials, International, West Conshohocken, PA, 19428.",
"    </li>",
"    <li>",
"     ASTM D6499: Standard test method for the immunological measurement of antigenic protein in natural rubber and its products. American Society for Testing Materials, International, West Conshohocken, PA, 19428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/28\">",
"      Yeang HY, Arif SA, Yusof F, Sunderasan E. Allergenic proteins of natural rubber latex. Methods 2002; 27:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/29\">",
"      Sussman GL, Beezhold DH, Kurup VP. Allergens and natural rubber proteins. J Allergy Clin Immunol 2002; 110:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/30\">",
"      Palosuo T, Alenius H, Turjanmaa K. Quantitation of latex allergens. Methods 2002; 27:52.",
"     </a>",
"    </li>",
"    <li>",
"     ASTM D7427-08. Standard test method for immunological measurement of four principal allergenic proteins (Hev b 1, 3, 5, 6.02) in natural rubber and its products derived from latex. American Society for Testing Materials, International, West Conshohocken, PA, 19428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/32\">",
"      Palosuo T, Reinikka-Railo H, Kautiainen H, et al. Latex allergy: the sum quantity of four major allergens shows the allergenic potential of medical gloves. Allergy 2007; 62:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/33\">",
"      Renaud MY. Composition of synthetic latexes used for manufacturing gloves by dipping processes. Clin Rev Allergy 1993; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/34\">",
"      Siler DJ, Cornish K, Hamilton RG. Absence of cross-reactivity of IgE antibodies from subjects allergic to Hevea brasiliensis latex with a new source of natural rubber latex from guayule (Parthenium argentatum). J Allergy Clin Immunol 1996; 98:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/35\">",
"      Carey AB, Cornish K, Schrank P, et al. Cross-reactivity of alternate plant sources of latex in subjects with systemic IgE-mediated sensitivity to Hevea brasiliensis latex. Ann Allergy Asthma Immunol 1995; 74:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/36\">",
"      Gentili A, Lima M, Ricci G, et al. Secondary prevention of latex allergy in children: analysis of results. Pediatr Med Chir 2006; 28:83.",
"     </a>",
"    </li>",
"    <li>",
"     American Latex Allergy Association www.latexallergyresources.org (Accessed on February 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/38\">",
"      Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/39\">",
"      Turjanmaa K, Palosuo T, Alenius H, et al. Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract. Allergy 1997; 52:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/40\">",
"      Sastre J, Fern&aacute;ndez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/41\">",
"      Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002; 95:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/42\">",
"      Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/43\">",
"      Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006; 22:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/44\">",
"      Nucera E, Schiavino D, Pollastrini E, et al. Sublingual desensitization in children with congenital malformations and latex allergy. Pediatr Allergy Immunol 2006; 17:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/45\">",
"      Lasa Luaces EM, Tabar Purroy AI, Garc&iacute;a Figueroa BE, et al. Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children. Ann Allergy Asthma Immunol 2012; 108:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/46\">",
"      Cister&oacute; Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol 2004; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/47\">",
"      Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/48\">",
"      Buyukozturk S, Gelincik A, Oz��eker F, et al. Latex sublingual immunotherapy: can its safety be predicted? Ann Allergy Asthma Immunol 2010; 104:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40070/abstract/49\">",
"      Rolland JM, Drew AC, O'Hehir RE. Advances in development of hypoallergenic latex immunotherapy. Curr Opin Allergy Clin Immunol 2005; 5:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5554 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40070=[""].join("\n");
var outline_f39_8_40070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MANAGEMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSTITUTIONAL AVOIDANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDIVIDUAL AVOIDANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEVEA ALLERGEN CONTENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEVEA LATEX ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT APPROACH IN THE WORKPLACE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT BY THE INDIVIDUAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/5/39004\" title=\"table 1\">",
"      Sources of latex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/2/10285\" title=\"table 2\">",
"      Latex allergens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40071="Adrenal hyperandrogenism";
var content_f39_8_40071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adrenal hyperandrogenism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     George P Chrousos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40071/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/8/40071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are a prominent source of androgen, particularly in children and women. Excess adrenal androgen secretion occurs in several different patient groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a common and well-recognized cause of virilization in infants and children, and an occasional cause of hirsutism and virilization in women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"       \"Adrenal steroid biosynthesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=see_link\">",
"       \"Pathogenesis and causes of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It can occur in men, in whom it has few clinical manifestations.",
"     </li>",
"     <li>",
"      It may contribute to the clinical findings in some patients with Cushing's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of adrenal androgen synthesis and disorders associated with excess adrenal androgen secretion. More detailed discussions of individual disorders are found separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL ADRENAL ANDROGEN SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens are byproducts of the synthesis of cortisol in the adrenal glands. As a result, the major determinant of their production is corticotropin (ACTH). The primary adrenal androgens are dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA sulfate) (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"mobipreview.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ). Less than 10 percent of DHEA and DHEA sulfate are produced by the testes or ovaries.",
"   </p>",
"   <p>",
"    DHEA and DHEA sulfate have little if any intrinsic androgenic activity. However, small amounts are converted to androstenedione and then to testosterone (and to estrogen) in both the adrenal glands and peripheral tissues, including hair follicles, sebaceous glands, the prostate, external genitalia, and adipose tissue. Thus, while excess secretion of DHEA and DHEA sulfate defines adrenal hyperandrogenism, the hirsutism and virilization are in fact caused by the more potent androgens, androstenedione and testosterone. DHEA and DHEA sulfate are metabolized primarily by reduction and conjugation to sulfates or glucuronides in the liver; the metabolites of these steroids and androstenedione are excreted as 17-ketosteroids in the urine.",
"   </p>",
"   <p>",
"    DHEA and DHEA sulfate are secreted in small amounts during infancy and early childhood. Their secretion gradually increases during late childhood, and the increase correlates with the development of small amounts of pubic hair in older but still prepubertal children, a phenomenon known as",
"    <strong>",
"     adrenarche",
"    </strong>",
"    . The cause of this increase in androgen secretion is not known. ACTH and cortisol secretion do not increase, suggesting that ACTH is not responsible. Other proopiomelanocortin (POMC)-derived peptides or a postulated, but never confirmed, adrenal androgen-stimulating hormone may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Alternatively, the cause may be a programmed shift in intraadrenal regulatory factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23302?source=see_link\">",
"     \"Normal adrenarche\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men, less than 5 percent of testosterone is derived from the adrenal or from adrenal precursors in peripheral tissues. In women, however, androstenedione and testosterone secreted by the adrenals and produced peripherally from DHEA and DHEA sulfate contribute substantially to total androgen production. In the follicular phase of the menstrual cycle, as an example, the adrenals directly or indirectly account for about 65 percent of testosterone production. In the midcycle, the ovarian contribution increases, so that the adrenals contribute only about 40 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link&amp;anchor=H3#H3\">",
"     \"Androgen production and therapy in women\", section on 'Premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both normal women and men, serum DHEA and DHEA sulfate concentrations rise throughout puberty and for a few years thereafter, reaching a peak in the third decade of life (the concentrations of DHEA sulfate are 100 to 1000 times higher than those of DHEA at all ages). Thereafter, they decline progressively; by age 80 years, the concentrations are only about 25 percent of those at age 25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/3\">",
"     3",
"    </a>",
"    ]. The cause or consequences, if any, of this decline are not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of adrenal hyperandrogenism vary with the age at onset and the sex of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prepubertal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prepubertal children of both sexes, androgen excess from any source increases height velocity, somatic development, and skeletal maturation. Epiphyseal fusion may occur prematurely, leading to short adult height. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"     \"Premature adrenarche\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings vary with the sex of the child:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In prepubertal boys, increases in androgen exposure causes virilization manifested by penile enlargement, growth of hair in androgen-dependent areas, deepening of the voice, and development of other secondary sexual characteristics (eg, isosexual precocious puberty).",
"     </li>",
"     <li>",
"      In prepubertal girls, androgen excess causes hirsutism, acne, and clitoromegaly (eg, heterosexual precocious puberty).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pubertal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pubertal boys, androgen excess increases the rate of progression of puberty and skeletal maturation, which can lead to premature epiphyseal fusion, thereby decreasing adult height. However, pubertal development and growth may also be arrested in boys who have hypercortisolism (Cushing's syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/4\">",
"     4",
"    </a>",
"    ], because cortisol excess inhibits pituitary-gonadal function and growth hormone secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pubertal girls, androgen excess causes virilization, primary or secondary amenorrhea, and increased skeletal maturation. As in boys, concurrent hypercortisolism may cause gonadal suppression and stunt linear growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adult men, adrenal androgen excess has little effect (ie, hair growth or muscle mass do not increase; however, acne and hirsutism in early puberty may occur). It does, however, inhibit gonadotropin secretion so that testes size, testicular testosterone secretion, and spermatogenesis may decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercortisolism has similar effects on pituitary-gonadal function. As a result, men with Cushing's syndrome may have some clinical manifestations of hypogonadism (eg, decreased hair growth, loss of muscle mass, loss of libido, and low serum testosterone concentrations), despite having adrenal androgen hypersecretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adult women, increased adrenal androgen production causes hirsutism, acne, male pattern baldness, menstrual irregularities, oligomenorrhea or amenorrhea, infertility, and even frank virilization. As in men, hypercortisolism in women inhibits pituitary-gonadal secretion, causing oligomenorrhea or amenorrhea and infertility, but not signs of androgen excess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Menstrual irregularities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/49/11034?source=see_link&amp;anchor=H12#H12\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Female reproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIMARY ADRENAL CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive adrenal production of androgens may occur as a result of both acquired and inherited adrenal diseases and other diseases that affect adrenal function (",
"    <a class=\"graphic graphic_table graphicRef56633 \" href=\"mobipreview.htm?32/57/33691\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Premature adrenarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature adrenarche is the appearance of pubic or axillary hair before the age of eight years in girls and nine years in boys, without other signs of puberty or virilization and without an advance in bone age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/7\">",
"     7",
"    </a>",
"    ]. It is more common in girls than in boys, usually occurs after the age of six years, and is not progressive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"     \"Premature adrenarche\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare genetic defect in DHEA sulfation, caused by a mutation in the gene encoding the sulfate donor PAPSS2, has been described. This mutation results in premature pubarche (isolated premature appearance of sexual hair), hirsutism, acne, oligomenorrhea, and very low (undetectable) DHEA-S levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adrenal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both benign and malignant adrenal tumors or bilateral macronodular adrenal hyperplasia can produce mainly or only androgens, including testosterone.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437758\">",
"    <span class=\"h3\">",
"     Adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen-secreting adrenal",
"    <strong>",
"     adenomas",
"    </strong>",
"    are rare. Affected patients have high serum androgen concentrations that do not fall in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ; in rare cases, the tumor secretes only testosterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/8\">",
"     8",
"    </a>",
"    ]. These patients usually do not have marked clinical or biochemical androgen excess. The tumors are typically small (diameter less than 4 cm), but are generally visible on computed tomography (CT) or magnetic resonance (MR) imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Androgen and estrogen-secreting tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437771\">",
"    <span class=\"h3\">",
"     Carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen-secreting adrenal",
"    <strong>",
"     carcinomas",
"    </strong>",
"    are more common than adenomas. These tumors characteristically produce androgens, many steroid intermediates, and sometimes cortisol. Some patients have a palpable abdominal mass or metastatic disease at the time of diagnosis, and many have clinical manifestations of both cortisol and androgen excess. Nearly all patients have very high serum DHEA and DHEA sulfate concentrations and urinary 17-ketosteroid excretion, and the values do not fall in response to high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Serum cortisol concentrations and urinary cortisol excretion are often increased.",
"    <br/>",
"    <br/>",
"    Most adrenal carcinomas are larger than 5 cm in diameter and have already invaded the capsule of the gland or neighboring tissues by the time they are discovered. The almost universal recurrence after resection of the primary tumor indicates that micrometastases are present in patients with even small carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437788\">",
"    <span class=\"h3\">",
"     Bilateral macronodular adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients with bilateral macronodular adrenal hyperplasia present with subclinical or overt Cushing&rsquo;s syndrome, some have co-secretion of cortisol with other steroids, including adrenal androgens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .) In rare patients with bilateral macronodular adrenal hyperplasia, only adrenal androgens were secreted, causing virilization in a woman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/9\">",
"     9",
"    </a>",
"    ] or no hormonal symptoms in a male patient, despite marked elevation of DHEA, DHEA-S, and androstenedione [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACTH-DEPENDENT CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several forms of adrenal hyperandrogenism that are mediated by ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Congenital adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital adrenal hyperplasia is the prototypic disorder of adrenal androgen secretion. Hyperandrogenism occurs in those disorders in which cortisol synthesis is impaired but the androgen secretory pathway is intact. These include CYP21A2 (21-hydroxylase) and CYP11B1 (11-beta-hydroxylase) deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17505362\">",
"    <span class=\"h3\">",
"     Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)",
"    </span>",
"    &nbsp;&mdash;&nbsp;11-beta-hydroxysteroid dehydrogenase type 1 deficiency has also been referred to as \"apparent cortisone reductase deficiency.\" The type 1 enzyme converts the inactive cortisone to cortisol in the liver and other tissues. Deficiency of this enzyme is compensated for by ACTH hypersecretion in a mechanism similar to that described for glucocorticoid resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/11\">",
"     11",
"    </a>",
"    ]. This disorder is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link&amp;anchor=H27#H27\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\", section on 'Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ACTH-dependent Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTH-dependent Cushing's syndrome is the most common cause of endogenous hypercortisolism, most often caused by a corticotroph adenoma of the pituitary, occasionally by ectopic ACTH secretion, and very rarely by excess corticotropin-releasing hormone (CRH) secretion. Thus, cortisol secretion should be evaluated in any adult patient with androgen excess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary glucocorticoid resistance syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare syndrome of glucocorticoid resistance is due to inactivating mutations in the gene for the glucocorticoid receptor and results in partial resistance to the actions of cortisol in all tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result of pituitary resistance, there are increases in ACTH secretion and therefore in the secretion of cortisol, adrenal androgens, and the mineralocorticoid 11-deoxycorticosterone. The high serum cortisol concentrations maintain normal or near-normal glucocorticoid activity in tissues. Thus, the manifestations of glucocorticoid resistance vary from none, to chronic fatigue (perhaps reflecting glucocorticoid deficiency), to variable degrees of hyperandrogenism or mineralocorticoid excess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=see_link&amp;anchor=H12#H12\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Familial glucocorticoid resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional woman with marked hyperprolactinemia due to a lactotroph adenoma has slight hirsutism and slightly high serum DHEA, DHEA sulfate, and androstenedione concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The cause of the hyperandrogenism is uncertain. Serum prolactin need not be measured in hirsute women unless they have other manifestations of hyperprolactinemia such as oligomenorrhea, amenorrhea, or especially galactorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Exogenous DHEA intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA has been studied as a potential therapy for a number of disorders including adrenal insufficiency, depression, menopausal symptoms, fibromyalgia, and as a possible anti-aging agent. However, the clinical benefits and safety of DHEA for any clinical indication is not well established. While DHEA is available by prescription only in most countries, in the United States, DHEA is widely available in stores that sell health foods and nutritional supplements. However, quality control (purity and potency) of these over-the-counter products has been shown to be quite poor. Current recommendations for DHEA use are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Placental aromatase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women who have placental aromatase or sulfatase deficiency are unable to produce estradiol and estriol from their precursors, DHEA sulfate and 16-alpha-DHEA sulfate, which come from the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Mothers with placental aromatase deficiency and their female fetuses have increases in serum DHEA, DHEA sulfate, and testosterone concentrations, and may have some signs of androgen excess. In comparison, women with placental sulfatase deficiency are asymptomatic but have low serum estriol concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7826623\">",
"    <span class=\"h2\">",
"     P450 oxidoreductase deficiency (apparent combined cyp17a1 and cyp21a2 deficiency)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In P450 oxidoreductase deficiency (ORD), affected neonates may present with severe undervirilization in boys and severe virilization in girls. Maternal virilization, associated with a high excretion of androgen metabolites beginning around midgestation, is frequently but not invariably observed during pregnancies with ORD. This disorder is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link&amp;anchor=H27#H27\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\", section on 'Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersecretion of androgens from the adrenal glands nearly always results in high serum DHEA and DHEA sulfate concentrations, and one or both of these compounds (and serum testosterone) should be measured in any hirsute or virilized woman in whom the cause is not obvious. The results of measurements of serum DHEA and DHEA sulfate must be interpreted on the basis of the patient's age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21445?source=see_link&amp;anchor=H2#H2\">",
"     \"Measurement of adrenal androgens\", section on 'Serum DHEA and DHEA sulfate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of measuring serum DHEA or DHEA sulfate is that a high value in a hirsute or virilized patient strongly suggests that the patient has adrenal hyperandrogenism, whereas serum testosterone values are high in patients with either adrenal or ovarian hyperandrogenism. As an example, women with idiopathic hirsutism or the polycystic ovary syndrome, the most common causes of hirsutism and virilization in women, have normal or very minimally elevated serum DHEA and DHEA sulfate concentrations. A serum DHEA sulfate concentration above 500",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (13.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in a young woman strongly suggests the presence of an adrenal tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21445?source=see_link\">",
"     \"Measurement of adrenal androgens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most androgen-secreting adrenal tumors can be identified by CT or MR imaging. Adrenal masses with low signal intensity on T1- and T2-weighted MR images are usually adenomas, whereas carcinomas have low signal intensity on T1-weighted images and enhanced activity on T2-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65020 \" href=\"mobipreview.htm?23/59/24496\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62315 \" href=\"mobipreview.htm?0/9/158\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prognosis of patients with adrenal hyperandrogenism vary with the underlying cause.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Premature adrenarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatment is needed besides reassurance. Pubertal development usually begins at the expected time. When associated with obesity or insulin resistance, appropriate advice for diet and lifestyle changes should be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"     \"Premature adrenarche\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When associated with late onset congenital adrenal hyperplasia, appropriate glucocorticoid replacement is given. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adrenal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for all patients with hormone-secreting adrenal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Surgery is the initial treatment for patients with adrenocortical carcinoma and is technically feasible in most. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of adrenocortical adenomas\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Congenital adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital adrenal hyperplasia are treated with a glucocorticoid and often a mineralocorticoid. (See appropriate topic reviews for the specific type of enzyme deficiency.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     ACTH-dependent Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ACTH-dependent Cushing's syndrome due to a corticotroph adenoma should be treated with pituitary surgery. Patients with ectopic ACTH- or CRH-secreting tumors are more difficult to treat. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Glucocorticoid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with glucocorticoid resistance should be treated with appropriately titrated doses of a glucocorticoid that has no intrinsic mineralocorticoid activity, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40071/abstract/6\">",
"     6",
"    </a>",
"    ]. The goals of therapy are to reduce ACTH and therefore adrenal androgen (and mineralocorticoid) secretion, taking care not to cause iatrogenic Cushing's syndrome. Women can be given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    to block the action of androgen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=see_link&amp;anchor=H12#H12\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Familial glucocorticoid resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hyperprolactinemia varies with the cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Placental enzyme deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with placental sulfatase deficiency need no therapy. Those with aromatase deficiency who have female fetuses could be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , which crosses the placenta and inhibits fetal adrenal function. However, the efficacy of this approach is not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31236?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and management of gestational hyperandrogenism\", section on 'Placental aromatase deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17505220\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are a prominent source of androgens. In fact, dehydroepiandrosterone&nbsp;(DHEA) and DHEA sulfate are the most abundant products of the adrenal glands. The major determinant of their production is corticotropin (ACTH) (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"mobipreview.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ). Less than 10 percent of DHEA and DHEA sulfate are produced by the testes or ovaries.",
"   </p>",
"   <p>",
"    DHEA and DHEA sulfate have little, if any, intrinsic androgenic activity. However, small amounts are converted to androstenedione and then to testosterone (and to estrogen) in both the adrenal glands and peripheral tissues, including hair follicles, sebaceous glands, the prostate, external genitalia, and adipose tissue. Thus, while excess secretion of DHEA and DHEA sulfate defines adrenal hyperandrogenism, the hirsutism and virilization are, in fact, caused by the more potent androgens, androstenedione and testosterone.",
"   </p>",
"   <p>",
"    Primary adrenal causes of adrenal hyperandrogenism include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature adrenarche (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"       \"Premature adrenarche\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adrenal tumors: adenomas and carcinomas, and bilateral macronodular adrenal hyperplasia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACTH-dependent causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital adrenal hyperplasia (common forms such as 21-hydroxylase deficiency, as well as others) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Congenital adrenal hyperplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      ACTH-dependent Cushing&rsquo;s syndrome (see",
"      <a class=\"local\" href=\"#H12\">",
"       'ACTH-dependent Cushing's syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary glucocorticoid resistance syndrome (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary glucocorticoid resistance syndrome'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperprolactinemia (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Hyperprolactinemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Exogenous DHEA intake (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Exogenous DHEA intake'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Placental aromatase deficiency (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Placental aromatase deficiency'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of adrenal hyperandrogenism depends upon the underlying cause.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/1\">",
"      Parker LN, Lifrak ET, Odell WD. A 60,000 molecular weight human pituitary glycopeptide stimulates adrenal androgen secretion. Endocrinology 1983; 113:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/2\">",
"      Anderson DC. The adrenal androgen-stimulating hormone does not exist. Lancet 1980; 2:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/3\">",
"      Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/4\">",
"      Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/5\">",
"      Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992; 267:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/6\">",
"      Charmandari E, Kino T. Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes. Eur J Clin Invest 2010; 40:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/7\">",
"      SILVERMAN SH, MIGEON C, ROSEMBERG E, WILKINS L. Precocious growth of sexual hair without other secondary sexual development; premature pubarche, a constitutional variation of adolescence. Pediatrics 1952; 10:426.",
"     </a>",
"    </li>",
"    <li>",
"     Tsigos C, Kamilaris TC, Chrousos GP. Adrenal diseases. In: Diagnostic Endocrinology, Moore WT, Eastman RC (Eds), Decker, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/9\">",
"      Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/10\">",
"      Ghayee HK, Rege J, Watumull LM, et al. Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. J Clin Endocrinol Metab 2011; 96:E243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/11\">",
"      Chrousos GP. Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci U S A 2004; 101:6329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/12\">",
"      Glickman SP, Rosenfield RL, Bergenstal RM, Helke J. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab 1982; 55:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/13\">",
"      Lobo RA, Kletzky OA. Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. J Clin Endocrinol Metab 1983; 56:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/14\">",
"      Tabei T, Heinrichs WL. Diagnosis of placental sulfatase deficiency.. Am J Obstet Gynecol 1976; 124:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/15\">",
"      Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991; 72:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/16\">",
"      Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.",
"     </a>",
"    </li>",
"    <li>",
"     Flack MR, Chrousos GP. Neoplasms of the adrenal cortex. In: Cancer Medicine, Holland R, et al (Eds), Lea &amp; Febiger, New York 1996. p.1563.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/18\">",
"      Cizza G, Dorn LD, Lotsikas A, et al. Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. Horm Metab Res 2001; 33:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40071/abstract/19\">",
"      Chrousos GP. Is laparoscopic adrenalectomy suitable for all adrenal masses? Nat Clin Pract Endocrinol Metab 2007; 3:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 123 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40071=[""].join("\n");
var outline_f39_8_40071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17505220\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL ADRENAL ANDROGEN SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pubertal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIMARY ADRENAL CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adrenal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437758\">",
"      - Adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437771\">",
"      - Carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437788\">",
"      - Bilateral macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACTH-DEPENDENT CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17505362\">",
"      - Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACTH-dependent Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary glucocorticoid resistance syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Exogenous DHEA intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Placental aromatase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7826623\">",
"      P450 oxidoreductase deficiency (apparent combined cyp17a1 and cyp21a2 deficiency)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adrenal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ACTH-dependent Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Glucocorticoid resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Placental enzyme deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17505220\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/123|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/59/24496\" title=\"diagnostic image 1\">",
"      Adrenal adenoma MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/9/158\" title=\"diagnostic image 2\">",
"      Adrenal carcinoma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/123|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/123|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/57/33691\" title=\"table 1\">",
"      Causes of adrenal hyperandrogenism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18470?source=related_link\">",
"      Causes of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31236?source=related_link\">",
"      Diagnosis and management of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=related_link\">",
"      Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21445?source=related_link\">",
"      Measurement of adrenal androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23302?source=related_link\">",
"      Normal adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=related_link\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40072="IPH portal tract fibrosis";
var content_f39_8_40072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic portal hypertension (IPH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Masson's trichrome stain of a liver biopsy specimen in a patient with IPH showing portal tract fibrosis and mild chronic inflammation. There is no visible portal vein radicle. Some dilated aberrant vascular structures can be seen (black arrows) at the periphery of the portal tract. A relatively small bile duct (BD: blue arrow) and hepatic artery (HA: red arrow) are visible in the portal triad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rosa Miquel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40072=[""].join("\n");
var outline_f39_8_40072=null;
var title_f39_8_40073="Parathyroid and mineral metabolism after renal transplantation";
var content_f39_8_40073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid and mineral metabolism after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Sri Yarlagadda, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     David W Butterly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40073/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/8/40073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease is associated with a cascade of events that adversely affect mineral metabolism and lead to renal osteodystrophy. Included in this group are initial phosphate retention, secondary hyperparathyroidism, decreased synthesis of calcitriol, and the accumulation of &szlig;2-microglobulin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aluminum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful renal transplantation, by normalizing urinary phosphate and &szlig;2-microglobulin excretion and renal calcitriol production, reverses many of these abnormalities in mineral and bone metabolism, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A fall in the plasma phosphate concentration to normal",
"     </li>",
"     <li>",
"      A reduction in plasma PTH levels",
"     </li>",
"     <li>",
"      A decrease in plasma alkaline phosphatase levels, indicative of less bone resorption",
"     </li>",
"     <li>",
"      Mobilization of soft tissue calcifications, as correction of hyperphosphatemia markedly lowers the calcium-phosphate product",
"     </li>",
"     <li>",
"      Improvement in aluminum bone disease",
"     </li>",
"     <li>",
"      Prevention of progression of amyloid osteodystrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the degree of improvement is frequently incomplete. The primary abnormalities that can persist after transplantation are hyperparathyroidism, aluminum and beta2-microglobulin accumulation, and diabetic bone disease. In addition, osteopenia and osteonecrosis are important causes of long-term morbidity in transplant recipients.",
"   </p>",
"   <p>",
"    Parathyroid and mineral metabolism after renal transplantation will be reviewed here. The related issue of osteoporosis after solid organ transplantation in general is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERSISTENT HYPERPARATHYROIDISM AND HYPERCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hyperparathyroidism (HPT) can be observed after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3,4,6-13\">",
"     3,4,6-13",
"    </a>",
"    ]. Some have reported that the incidence is approximately 30 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/14\">",
"     14",
"    </a>",
"    ]. The development of hypercalcemia correlates with the duration of dialysis and parathyroid gland size and appears to be secondary to hyperplasia of the parathyroid glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/8\">",
"     8",
"    </a>",
"    ]. The degree of parathyroid hyperplasia can be so great in this setting that, although the parathyroid glands involute after transplantation, this process takes a few months (if mild) to several years to reach completion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3,4,6,7\">",
"     3,4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional factor that can contribute to persistent hyperparathyroidism is nodular transformation to monoclonal growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], which is more likely to occur in areas of reduced vitamin D receptor density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/17\">",
"     17",
"    </a>",
"    ]. In this setting, the polyclonal glands would gradually regress, resulting in a discrete parathyroid adenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/18\">",
"     18",
"    </a>",
"    ]. Persistent hyperparathyroidism is the most common cause of hypercalcemia in renal transplant patients.",
"   </p>",
"   <p>",
"    In addition to hyperparathyroidism, other factors can also contribute to an elevation in the plasma calcium concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resorption of soft tissue calcium phosphate deposits, which is often associated with persistent hyperphosphatemia (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normalization of calcitriol production, which both increases the PTH effect on bone and directly enhances intestinal calcium absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/12,19\">",
"       12,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enhanced tubular calcium resorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To a lesser degree, a rise in the plasma albumin concentration (due to better nutrition) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/4\">",
"       4",
"      </a>",
"      ]. This will raise the total plasma calcium concentration via increased binding but will have no effect on the physiologically important free or ionized calcium concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=see_link\">",
"       \"Relation between total and ionized serum calcium concentration\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In those patients who develop hypercalcemia, the plasma calcium concentration frequently begins to rise in the first 10 days after transplantation; however, this response can be delayed for six months or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In some cases, acute severe hypercalcemia (plasma calcium concentration above 12.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    occurs soon after transplantation, and can cause acute allograft dysfunction and rarely calciphylaxis, in which vascular calcification can lead to local ischemic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients typically have preexisting severe secondary hyperparathyroidism. Fortunately, this form of marked hypercalcemia is less frequent at the present time, due to improved management of phosphate and vitamin D balance in patients with chronic renal failure and those on dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent HPT can affect the outcome of renal transplant recipients in several ways. Uncontrolled HPT and hypercalcemia are risk factors for posttransplant bone disease. In addition, tubulointerstitial calcifications on early protocol biopsies have been described in patients with persistent hyperparathyroidism that were associated with inferior graft outcomes after one year of transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/20\">",
"     20",
"    </a>",
"    ]. Lastly, high PTH levels and hypercalcemia promote vascular calcifications, which are associated with an increased posttransplant morbidity and mortality in renal transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all these reasons, effective control of persistent HPT is an important therapeutic goal after renal transplantation.",
"   </p>",
"   <p>",
"    As hypercalcemia limits the use of vitamin D analogs, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , a calcimimetic drug, is being increasingly studied. All studies found that serum calcium concentration normalizes with cinacalcet therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. The effect of cinacalcet on PTH and serum phosphorus varies across studies. There was no decrease in PTH level reported in two studies, while PTH decreased in the rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Serum phosphorus level increased in most and did not change in three studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/22,25,26\">",
"     22,25,26",
"    </a>",
"    ]. Similarly, three studies have reported increased calciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    and immunosuppressive therapy was evaluated in 14 renal transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study, one week of cinacalcet therapy induced a moderate but significant decrease in systemic exposure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    pharmacokinetics were unaffected.",
"   </p>",
"   <p>",
"    Though not approved for use in CKD or in post-renal transplant patients,&nbsp;the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    along with careful monitoring may be an alternative to parathyroidectomy.&nbsp;However, some clinicians would use cinacalcet as an alternative to parathyroidectomy only in patients not able or unwilling to undergo a parathyroidectomy. Further studies are needed to determine the relative",
"    <span class=\"nowrap\">",
"     risk/benefits",
"    </span>",
"    to surgical and medical therapy of tertiary HPT post renal transplant.",
"   </p>",
"   <p>",
"    There are two major indications for parathyroidectomy in renal transplant patients: severe symptomatic hypercalcemia, usually occurring in the early posttransplant period, and persistent, marked hypercalcemia. There are many surgical approaches. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .) The complications that can result from parathyroid surgery include hypocalcemia (that may be refractory to usual therapy) and low turnover or adynamic bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ALUMINUM TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation quickly reverses factors leading to aluminum accumulation. Osteomalacia is the type of renal osteodystrophy most often caused by aluminum excess; however, with the reduced use of aluminum, its prevalence has markedly decreased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HYPOPHOSPHATEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hypophosphatemia is primarily induced by phosphate wasting in the urine due both to hyperparathyroidism and to PTH-independent pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/30\">",
"     30",
"    </a>",
"    ]. One such pathway that is instrumental in the early posttransplant period is increased FGF-23 (eg, fibroblast growth factor-23) levels, which can accumulate in chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Markedly elevated FGF-23 levels before renal transplantation may result in persistent elevation of FGF-23 levels after transplant and accentuate hypophosphatemia in the posttransplant period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/34\">",
"     34",
"    </a>",
"    ]. This condition is now referred to as tertiary hyperphosphatoninism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/31,34\">",
"     31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phosphate wasting and relatively low serum phosphate concentrations may persist more than a year out from transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/13\">",
"     13",
"    </a>",
"    ]. By contrast to the early posttransplantation period, persistent hyperparathyroidism but not increased FGF-23 appears to underlie the phosphate wasting that persists beyond one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/35\">",
"     35",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/13\">",
"     13",
"    </a>",
"    ] have suggested that MTOR inhibitors contribute to hypophosphatemia.",
"   </p>",
"   <p>",
"    Plasma phosphate levels below 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32 to 0.48",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    can cause muscle weakness and possibly osteomalacia (although the latter has not been a consistent finding).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment generally consists of phosphate supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    .) One important exception is the patient with significant persistent hyperparathyroidism as detected by elevated plasma intact PTH levels. In this setting, the administration of phosphate can exacerbate the hyperparathyroidism (particularly in patients who are not hypercalcemic), in part by complexing with calcium and lowering intestinal calcium absorption.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    enhances renal tubular phosphate reabsorption in animals and humans. In a preliminary study, the administration of dipyridamole successfully elevated serum phosphate levels in hypophosphatemic renal transplant recipients after three weeks of therapy (1.94 to 2.73",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIALYSIS-RELATED AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis-related amyloidosis is primarily induced by &szlig;2-microglobulin deposition as amyloid fibrils. The articular symptoms associated with disorder rapidly improve after renal transplantation. New cystic lesions are unusual, but resolution of existing cysts is rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POSTTRANSPLANT BONE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia and osteonecrosis (avascular necrosis), the two major osseous complications of renal transplantation, cause important long&ndash;term morbidity in renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]. Multiple factors appear to contribute to these disorders, including persistent uremia-induced abnormalities in calcium homeostasis and acquired defects in mineral metabolism induced by immunosuppressive medications. This has also been associated with both high and low serum PTH levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Osteopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies have demonstrated that bone loss occurs early and rapidly following transplantation of the kidney and other organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/38-44\">",
"     38-44",
"    </a>",
"    ]. The loss is principally due to a reduction in trabecular bone disease, although cortical bone may also be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/41,42,44-46\">",
"     41,42,44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report, for example, evaluated bone mineral density and bone histology in 20 living related donor renal transplant recipients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/44\">",
"     44",
"    </a>",
"    ]. These patients lost 6.8 percent of their initial bone mass during the first six months and developed a low&ndash;turnover bone disorder resembling that induced by glucocorticoids. By 18 months, bone loss had decreased 9.0 percent from baseline and 60 percent of the patients had bone marrow density below the fracture threshold. Similar findings were noted in a prospective evaluation of predominantly deceased donor renal transplant recipients: bone loss occurred at the rate of 1.6 percent",
"    <strong>",
"     per month",
"    </strong>",
"    during the first five months following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After this early period, bone loss continues in most patients although at a slower rate. One longitudinal study, for example, performed repeat bone density measurements in 70 renal transplant recipients with a mean time of 8.1 years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/47\">",
"     47",
"    </a>",
"    ]. The mean rate of bone loss was 1.7 percent per year.",
"   </p>",
"   <p>",
"    The development of osteopenia places the patient at increased risk for pathologic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/2,42,45,48\">",
"     2,42,45,48",
"    </a>",
"    ]. Data suggests that the location of the fractures may be either peripheral or central, with some evidence suggesting a higher incidence at peripheral locations (such as hands, ankles, and feet) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/45,49\">",
"     45,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttransplant bone loss involves both preexisting risk factors (such as hyperparathyroidism) and the adverse effects of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/2,38,45,50\">",
"     2,38,45,50",
"    </a>",
"    ]. Glucocorticoid-induced suppression of bone formation is the most important factor in the genesis of early and long-term bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/2,47,50,51\">",
"     2,47,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Steroids are directly toxic to osteoblasts and lead to increased osteoclast activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/52\">",
"     52",
"    </a>",
"    ]. They also have other effects that promote calcium loss and the development of osteopenia. These include decreased calcium absorption in the gut, reduced gonadal hormone production, diminished insulin-like growth factor&ndash;1 production, decreased sensitivity to PTH, increased in receptor activator of NFkappa beta ligand (RANKL), increased osteoclastogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/38,50,52\">",
"     38,50,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of preexisting hyperparathyroidism on the rate of bone loss have not been clarified, but could contribute to the excessive loss of cancellous bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/4\">",
"     4",
"    </a>",
"    ]. On the other hand, the resolution of hyperparathyroidism following transplantation, may result in increased cortical bone density.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    also may contribute to bone loss, especially in long&ndash;term survivors and in subjects treated only with cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/45,53-55\">",
"     45,53-55",
"    </a>",
"    ]. Clinically, although cyclosporine has been associated with bone loss, cyclosporine utilized in a corticosteroid-free regimen was not associated with significant bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H7#H7\">",
"     \"Drugs that affect bone metabolism\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    , another calcineurin inhibitor, also causes osteopenia in rats. Limited data is available concerning the clinical effect of tacrolimus on bone, with one study showing no difference in bone loss with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus tacrolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/43,56,57\">",
"     43,56,57",
"    </a>",
"    ]. Some limited evidence suggests that the ability to possibly use decreased amounts of corticosteroids with tacrolimus, versus that administered with cyclosporine, may result in increased bone mineral density among treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different therapies have been evaluated to prevent bone loss in the renal transplant recipient. The major agents that have assessed are vitamin D metabolites, antiresorptive agents, and calcitonin. Corticosteroid withdrawal is another strategy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a relative paucity of data concerning the effectiveness of prophylactic therapy using vitamin D metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/58-63\">",
"     58-63",
"    </a>",
"    ]. In one study, 111 renal transplant recipients were randomly assigned to either no treatment or active therapy with vitamin D (0.25",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    plus calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients were evaluated at zero, one, three, and six months after transplant using laboratory parameters and densitometry. During the first three months, a significant decrease in bone mineral density was observed in both groups. However, between the third and sixth months, the active therapy group had a slight recovery of bone loss, while the no treatment group exhibited continued decreases in bone density (total bone loss at six months of 2.6 and 5.0 percent for active and no treatment, respectively). Another study, however, found that the addition of vitamin D to calcium provided no significant additional benefit than calcium alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By comparison, there is consistent evidence that antiresorptive agents effectively prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treat bone loss early in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/64-71\">",
"       64-71",
"      </a>",
"      ]. This was best shown in a 2006 meta-analysis that evaluated five studies that involved 180 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/71\">",
"       71",
"      </a>",
"      ]. Bisphosphonates (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      , zoledronate, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      ) reduced bone mineral density declines at the lumbar spine (0.06",
"      <span class=\"nowrap\">",
"       g/cm2,",
"      </span>",
"      95% CI 0.05-0.08",
"      <span class=\"nowrap\">",
"       g/cm2)",
"      </span>",
"      and at the femoral neck (0.05",
"      <span class=\"nowrap\">",
"       g/cm2,",
"      </span>",
"      95% CI 0.00-0.11",
"      <span class=\"nowrap\">",
"       g/cm2)",
"      </span>",
"      within 6 to 12 months post-transplantation. One randomized trial showed preservation of bone mineral density associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      use among women but not men at 12 months after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/72\">",
"       72",
"      </a>",
"      ]. However, these results should be interpreted with caution since bone mineral density testing does not predict the type of underlying bone disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these reports, it is unclear whether antiresorptive therapy reduces the number of fractures since the pathogenesis of bone disease in solid organ recipients differs from that in patients with typical osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/74\">",
"     74",
"    </a>",
"    ]. As previously mentioned, most fractures in transplant patients occur in the appendicular skeleton (particularly the feet and ankles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/48\">",
"     48",
"    </a>",
"    ], while the axial skeleton and trabecular bone sites are most commonly involved in individuals with typical osteoporosis.",
"   </p>",
"   <p>",
"    Furthermore, since renal transplant recipients also suffer from an adynamic or low turnover bone lesion, the addition of agents that suppress bone remodeling may not improve the mechanical integrity of bone. This was shown in a study of 72 new renal transplant recipients who were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    with vitamin D plus calcium or only vitamin D plus calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/75\">",
"     75",
"    </a>",
"    ]. At six months, adynamic bone disease was observed in all patients receiving pamidronate compared to 50 percent in the control group.",
"   </p>",
"   <p>",
"    Since we do not routinely perform bone biopsies in patients on dialysis or after transplant, and persistent hyperparathyroidism could be associated with either low or high turnover bone disease, it is clinically difficult to avoid bisphosphonates in patients with preexisting adynamic bone disease and, therefore, avoid further worsening. This effect of bisphosphonates could be at least partially responsible for the lack of decrease in the incidence of fractures, despite treatment of osteoporosis in the transplant population.",
"   </p>",
"   <p>",
"    Thus, in addition to decreasing bone resorption, stimulation of bone formation by bone anabolic agents is also desirable.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     Recombinant human parathyroid hormone",
"    </a>",
"    1-34 (teriparatide) exerts anabolic effects on the skeleton when given intermittently and has shown preliminary promise for patients with glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/76\">",
"     76",
"    </a>",
"    ]. Teriparatide has been tested in kidney transplant patients. Twenty-six kidney transplant patients were treated with daily subcutaneous injections of 20 micrograms of teriparatide or placebo in a six-month double blind, randomized trial. Femoral neck BMD remained stable in the teriparatide group but decreased significantly in the placebo group. Lumbar spine and radial BMD, histomorphometric bone volume and bone matrix mineralization remained unchanged in both the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/77\">",
"     77",
"    </a>",
"    ]. At this time, we do not have adequate data to support the use of teriparatide in renal transplant patients.",
"   </p>",
"   <p>",
"    A 2005 systematic review of randomized control trials was performed to better understand the efficacy of different interventions to help prevent bone disease in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/78\">",
"     78",
"    </a>",
"    ]. Twenty-three eligible trials with 1209 patients were studied. Agents commonly studied were bisphosphonates, vitamin D analogues, with or without calcium, and calcitonin. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No reduction in risk for fracture was reported in any study.",
"     </li>",
"     <li>",
"      Compared with no treatment, improvements in bone mineral density at the lumbar spine were observed with bisphosphonates, vitamin D analogues, and calcitonin.",
"     </li>",
"     <li>",
"      Improvements in bone mineral density at the femoral neck were observed with bisphosphonates and vitamin D analogues versus no treatment. By comparison, one study found no relative benefit with calcitonin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Somewhat similar findings as the 2005 systematic review were reported in a prospective study of 60 renal transplant recipients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/14/37093?source=see_link\">",
"     alfacalcidol",
"    </a>",
"    , calcitonin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , or a control group, with all patients also receiving oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    . [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/79\">",
"     79",
"    </a>",
"    ]. At 12 months post-transplant, bone mineral density at the lumbar spine, femoral neck, and forearm had increased to a similar degree with all three agents, while it had decreased in the control group. These agents were well tolerated, although transient hypocalcemia was noted with alendronate and calcitonin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Monitoring and assessment of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to monitor bone mineral density in the renal transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/80\">",
"     80",
"    </a>",
"    ]. We suggest an initial assessment of the hip and spine prior to transplantation and at three months following transplantation using dual energy X&ndash;ray absorptiometry (DEXA).",
"   </p>",
"   <p>",
"    Those subjects displaying rapid bone loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a low initial bone density should be considered for treatment. In addition, other risk factors for future bone loss may influence therapeutic decisions, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low testosterone levels in males (which may be induced by glucocorticoids)",
"     </li>",
"     <li>",
"      Genetic predisposition &mdash; white race, small body habitus, positive family history",
"     </li>",
"     <li>",
"      Lifestyle factors, such as smoking and lack of exercise",
"     </li>",
"     <li>",
"      Impaired nutrition due, for example, to low dietary calcium intake or excess alcohol ingestion",
"     </li>",
"     <li>",
"      The degree of hyperparathyroidism and presence of diabetes mellitus",
"     </li>",
"     <li>",
"      Receiving a",
"      <span class=\"nowrap\">",
"       kidney/pancreas",
"      </span>",
"      transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO have published guidelines concerning the evaluation of bone disease in renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73,81\">",
"     73,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With",
"      <span class=\"nowrap\">",
"       K/DOQI,",
"      </span>",
"      DEXA scans should be obtained at time of transplant and one year and two years post-transplant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/81\">",
"       81",
"      </a>",
"      ]. If BMD t-score is equal to or less than -2 at the time of the transplant, or at subsequent evaluations, consideration should be given to therapy with bisphosphonates.",
"     </li>",
"     <li>",
"      With KDIGO, they suggest that, among those with GFRs greater than approximately 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 mm2, bone mineral density should be measured in the first three months post-transplant, if they are receiving corticosteroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if there are risk factors for osteoporosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73\">",
"       73",
"      </a>",
"      ]. A bone biopsy should also be considered, particularly prior to bisphosphonate therapy. By comparison, they suggest that BMD testing not be routine in patients with stage 4 to 5 CKD not yet on dialysis, since it does not predict the type of bone disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Approach to prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of clear evidence as to the optimal approach to the management of posttransplant bone disease, we recommend that the following regimen be considered in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/1,45,80\">",
"     1,45,80",
"    </a>",
"    ]: (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An effort should be made to find the lowest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose compatible with graft survival. However, significant osteopenia has been observed with prednisone doses as low as 7.5 to 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Calcium supplementation (1000 mg per day) should be considered in nonhypercalcemic patients, since glucocorticoid therapy reduces intestinal calcium absorption.",
"     </li>",
"     <li>",
"      The administration of vitamin D analogs (such as calcitriol) can further improve calcium absorption but at a significant risk of hypercalcemia and hypercalciuria, both of which may have adverse effects on renal function.",
"     </li>",
"     <li>",
"      If bone loss is severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rapid,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the patient has diabetes mellitus or has received a",
"      <span class=\"nowrap\">",
"       kidney/pancreas",
"      </span>",
"      transplant, consideration should be given to the administration of antiresorptive agents, such as the bisphosphonates (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ) or intranasal calcitonin, especially during the first six months after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/74\">",
"       74",
"      </a>",
"      ]. Additional studies are needed before routine use of these agents can be recommended.",
"     </li>",
"     <li>",
"      Because of possible safety and tolerance issues, we treat only high-risk patients with calcitonin, 100 units subcutaneously daily for the first month then every other day for the first six months. Nasal calcitonin may provide a more acceptable alternative. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43173?source=see_link\">",
"       \"Calcitonin in the prevention and treatment of osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight bearing exercises should be encouraged among all patients after transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KDIGO guidelines suggest that, among those with GFRs greater than approximately 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 mm2 and low bone mineral density, treatment with vitamin D,",
"    <span class=\"nowrap\">",
"     calcitriol/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/14/37093?source=see_link\">",
"      alfacalcidol",
"     </a>",
"     ,",
"    </span>",
"    or bisphosphonates should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73\">",
"     73",
"    </a>",
"    ]. The choice of these agents is determined by abnormal calcium, phosphate, PTH, alkaline phosphate, and 25(OH)D levels. A bone biopsy should also be considered, particularly prior to bisphosphonate therapy. In addition, management of those with low bone mineral density and GFRs less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.72 mm2 should be similar to that of non-transplant patients with stage 4 to 5 CKD not yet on dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis (avascular or ischemic necrosis) is probably the most debilitating of the musculoskeletal complications following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/18,82-84\">",
"     18,82-84",
"    </a>",
"    ]. It is characterized by the noninfectious death of marrow cells and associated trabeculae and osteocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/85\">",
"     85",
"    </a>",
"    ]. The weight bearing long bones are most often affected, particularly the femoral head. Osteonecrosis is usually multifocal with 50 to 70 percent of patients having more than one joint involved.",
"   </p>",
"   <p>",
"    Previous studies suggested an incidence of approximately 15 percent within three years; however, the risk has decreased over the last several decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. In a historic cohort study of over 40,000 renal transplant recipients, the incidence of hospitalization due to osteonecrosis was 7",
"    <span class=\"nowrap\">",
"     episodes/1000",
"    </span>",
"    person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of osteonecrosis is incompletely understood, but glucocorticoids are thought to play a central role. Increased intramarrow pressure, adipocyte hyperplasia, fat embolism, and microfractures leading to compromised vascular supply all may be involved in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/85,87\">",
"     85,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .) It is unclear whether osteopenia and preexisting hyperparathyroidism are independent risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is also unclear, with some but not all studies showing an increased incidence with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of osteonecrosis is made on clinical grounds with radiographic confirmation. The most sensitive radiologic technique is magnetic resonance imaging (MRI) which shows a dark segment in the femoral head with a peripheral high intensity rim on T1 weighted images. MRI scanning should therefore be performed in any patient renal transplant recipient with persistent knee, shoulder, or hip pain. The plain radiograph is the least sensitive screening method, whereas bone scanning has an intermediate sensitivity.",
"   </p>",
"   <p>",
"    The treatment of osteonecrosis is surgical as there is no proven medical therapy. Although steroids are pathogenetically important, reduction of the steroid dose has little therapeutic effect once osteonecrosis has developed. Many affected patients will eventually require joint replacement, although, vascularized bone grafts and core decompression show some promise when used in the early stages of the disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone pain and cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to osteopenia and osteonecrosis, a different bone pain syndrome has been described that occurs in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/89\">",
"     89",
"    </a>",
"    ]) and that is often temporally related to increased plasma cyclosporine levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/90\">",
"     90",
"    </a>",
"    ]. The mechanism by which this occurs and its possible relation to the development of osteonecrosis are not clear, but intraosseous vasoconstriction and hypertension may play a role. There are characteristic magnetic resonance imaging findings, which are consistent with",
"    <span class=\"nowrap\">",
"     edema/subclinical",
"    </span>",
"    trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Calcium channel blockers (such as sustained release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , 30 to 60 mg before bedtime) and a reduction in the calcineurin inhibitor dose appear to relieve the symptoms in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40073/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23740598\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease is associated with a cascade of events that adversely affect mineral metabolism. Successful renal transplantation reverses many of these abnormalities in mineral and bone metabolism, although the degree of improvement is frequently incomplete. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent hyperparathyroidism with or without hypercalcemia may be observed after kidney transplantation. Surgery is required for refractory cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Persistent hyperparathyroidism and hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteopenia and osteonecrosis are the two major osseous complications of renal transplantation, and are believed to be caused by multiple factors, including persistent uremia-induced abnormalities in calcium homeostasis and acquired defects in mineral metabolism induced by immunosuppressive medications. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Posttransplant bone disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to prevent and treat posttransplant bone disease include minimizing the use of glucocorticoids, providing supplemental calcium, treating vitamin D deficiency and encouraging weight bearing exercise. Antiresorptive agents such as bisphosphonates should also be considered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/1\">",
"      Heaf JG. Bone disease after renal transplantation. Transplantation 2003; 75:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/2\">",
"      Julian, BA, Benfield, M, Quarles, LD. Bone loss after organ transplantation. Transplant Rev 1993; 7:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/3\">",
"      Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992; 19:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/4\">",
"      Cundy T, Kanis JA, Heynen G, et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983; 52:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/5\">",
"      Bonarek H, Merville P, Bonarek M, et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/6\">",
"      D'Alessandro AM, Melzer JS, Pirsch JD, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 1989; 106:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/7\">",
"      David DS, Sakai S, Brennan BL, et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973; 289:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/8\">",
"      Garvin PJ, Castaneda M, Linderer R, Dickhans M. Management of hypercalcemic hyperparathyroidism after renal transplantation. Arch Surg 1985; 120:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/9\">",
"      Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982; 8:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/10\">",
"      Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/11\">",
"      Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/12\">",
"      Borchhardt K, Sulzbacher I, Benesch T, et al. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/13\">",
"      Sirilak S, Chatsrisak K, Ingsathit A, et al. Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol 2012; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/14\">",
"      Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/15\">",
"      Arnold A, Brown MF, Ure&ntilde;a P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/16\">",
"      Dr&uuml;eke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/17\">",
"      Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/18\">",
"      Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant 1989; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/19\">",
"      Bonnin MR, Gonz&aacute;lez MT, Huguet J, et al. 1,25-Dihydroxycholecalciferol as measured by a radioreceptor assay in normal subjects and patients after kidney transplantation. Clin Chem 1990; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/20\">",
"      Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/21\">",
"      Hern&aacute;ndez D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/22\">",
"      Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/23\">",
"      Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/24\">",
"      Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/25\">",
"      Szwarc I, Argil&eacute;s A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/26\">",
"      Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/27\">",
"      El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/28\">",
"      Kamar N, Gennero I, Spataru L, et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrol Dial Transplant 2008; 23:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/29\">",
"      Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/30\">",
"      Rosenbaum RW, Hruska KA, Korkor A, et al. Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 1981; 19:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/31\">",
"      Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/32\">",
"      Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104:p23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/33\">",
"      Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/34\">",
"      Evenepoel P, Naesens M, Claes K, et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/35\">",
"      Tataranni T, Biondi G, Cariello M, et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant 2011; 11:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/36\">",
"      Amb&uuml;hl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/37\">",
"      Balal M, Paydas S, Seyrek N, et al. Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients. Clin Nephrol 2005; 63:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/38\">",
"      Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/39\">",
"      Horber FF, Casez JP, Steiger U, et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/40\">",
"      Ulivieri FM, Piodi LP, Aroldi A, Cesana BM. Effect of kidney transplantation on bone mass and body composition in males. Transplantation 2002; 73:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/41\">",
"      Casez JP, Lippuner K, Horber FF, et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/42\">",
"      Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/43\">",
"      Marc&eacute;n R, Caballero C, Pascual J, et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006; 81:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/44\">",
"      Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/45\">",
"      Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis 2006; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/46\">",
"      Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994; 66:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/47\">",
"      Pichette V, Bonnardeaux A, Prudhomme L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996; 28:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/48\">",
"      Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol 2004; 24:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/49\">",
"      Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/50\">",
"      Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/51\">",
"      Monier-Faugere MC, Mawad H, Qi Q, et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/52\">",
"      Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/53\">",
"      Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/54\">",
"      Cayco AV, Wysolmerski J, Simpson C, et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/55\">",
"      Cuerto-Manzano, AM, Konel, S, Crowley, V, et al. Transplantation 2003; 74:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/56\">",
"      Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/57\">",
"      Monegal A, Navasa M, Gua&ntilde;abens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/58\">",
"      Cueto-Manzano AM, Konel S, Freemont AJ, et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000; 35:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/59\">",
"      De S&eacute;vaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002; 13:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/60\">",
"      Torres A, Garc&iacute;a S, G&oacute;mez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/61\">",
"      El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003; 14:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/62\">",
"      Wissing KM, Broeders N, Moreno-Reyes R, et al. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005; 79:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/63\">",
"      Lippuner K, Haller B, Casez JP, et al. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 1996; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/64\">",
"      Fan SL, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/65\">",
"      Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998; 66:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/66\">",
"      Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/67\">",
"      Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/68\">",
"      Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003; 63:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/69\">",
"      Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/70\">",
"      Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2002; 2:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/71\">",
"      Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/72\">",
"      Coco M, Pullman J, Cohen HW, et al. Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol 2012; 23:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/73\">",
"      KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/74\">",
"      Weber TJ, Quarles LD. Preventing bone loss after renal transplantation with bisphosphonates: we can... but should we? Kidney Int 2000; 57:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/75\">",
"      Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/76\">",
"      Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/77\">",
"      Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008; 8:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/78\">",
"      Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/79\">",
"      El-Agroudy AE, El-Husseini AA, El-Sayed M, et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005; 67:2039.",
"     </a>",
"    </li>",
"    <li>",
"     European best practice guidelines for renal transplantation. Nephrol Dial Transplant 2002; 17:(Suppl 4):43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/81\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/82\">",
"      Ibels LS, Alfrey AC, Huffer WE, Weil R 3rd. Aseptic necrosis of bone following renal transplantation: experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978; 57:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/83\">",
"      Metselaar HJ, van Steenberge EJ, Bijnen AB, et al. Incidence of osteonecrosis after renal transplantation. Acta Orthop Scand 1985; 56:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/84\">",
"      Parfrey PS, Farge D, Parfrey NA, et al. The decreased incidence of aseptic necrosis in renal transplant recipients--a case control study. Transplantation 1986; 41:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/85\">",
"      Zizic TM. Osteonecrosis. Curr Opin Rheumatol 1991; 3:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/86\">",
"      Abbott KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int 2002; 62:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/87\">",
"      Abbott KC, Koff J, Bohen EM, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation 2005; 79:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/88\">",
"      Tang S, Chan TM, Lui SL, et al. Risk factors for avascular bone necrosis after renal transplantation. Transplant Proc 2000; 32:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/89\">",
"      Goffin E, Vande Berg B, Devogelaer JP, et al. Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression. Clin Nephrol 2003; 59:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/90\">",
"      Gauthier VJ, Barbosa LM. Bone pain in transplant recipients responsive to calcium channel blockers. Ann Intern Med 1994; 121:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/91\">",
"      Goffin E. Transient bone marrow edema in renal transplantation: a distinct post-transplantation syndrome with a characteristic MRI appearance. Am J Transplant 2003; 3:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40073/abstract/92\">",
"      Coates PT, Tie M, Russ GR, Mathew TH. Transient bone marrow edema in renal transplantation: a distinct post-transplantation syndrome with a characteristic MRI appearance. Am J Transplant 2002; 2:467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7299 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40073=[""].join("\n");
var outline_f39_8_40073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23740598\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERSISTENT HYPERPARATHYROIDISM AND HYPERCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALUMINUM TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HYPOPHOSPHATEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIALYSIS-RELATED AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POSTTRANSPLANT BONE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Osteopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Monitoring and assessment of risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Approach to prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone pain and cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23740598\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40074="Initial treatment of depression in adults";
var content_f39_8_40074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of depression in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Paul Ciechanowski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/8/40074/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/8/40074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization ranks major depression among the most burdensome diseases in the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/1\">",
"     1",
"    </a>",
"    ]. The lifetime prevalence of major depression in the US community in 2001-2 was 16.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 5 to 10 percent of primary care patients meet DSM-IV criteria for major depression and 3 to 5 percent for dysthymia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The prevalence of major depression is estimated at 10 to 20 percent in patients with medical illnesses such as diabetes and heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major depression is a relapsing, remitting illness in most patients. Following a first episode, there is a greater than 40 percent rate of recurrence over a two-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/6\">",
"     6",
"    </a>",
"    ]; after two episodes, the risk of recurrence within five years is approximately 75 percent. Ten to 30 percent of patients treated for a major depressive episode will have an incomplete recovery, with persistent symptoms or dysthymia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the initial treatment of depression. Continuation and maintenance treatment of depression; the treatment of resistant depression; and the clinical manifestations, diagnosis, and prognosis of depression are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=see_link\">",
"       \"Unipolar depression in adults: Continuation and maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have symptoms of depression should be evaluated with a history, physical examination, and limited laboratory testing (if indicated) to rule out secondary medical causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Making the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distinguishing unipolar and bipolar depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with depressive symptoms should be screened for bipolar disorder. The three types of bipolar disorder defined in the American Psychiatric Association&rsquo;s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bipolar I",
"     </li>",
"     <li>",
"      Bipolar II",
"     </li>",
"     <li>",
"      Bipolar disorder not otherwise specified (NOS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with bipolar disorder are frequently misdiagnosed as having unipolar depression, particularly patients with bipolar II disorder or bipolar disorder NOS who do not exhibit overt symptoms of mania. As an example, a study of 576 primary care patients with a working diagnosis of unipolar depression estimated that between 10 and 22 percent of the patients met DSM-IV criteria for bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/9\">",
"     9",
"    </a>",
"    ]. Additional information about the diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Establishing the diagnosis of bipolar disorder is essential to appropriately treat bipolar depression and to prevent mania or hypomania. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Suicidal ideation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment for the presence of suicidal ideation is of paramount importance in all depressed patients. However, the ability of clinicians to predict suicide attempts and completed suicide is poor.",
"   </p>",
"   <p>",
"    Evaluation for suicide risk should include assessment of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of suicidal or homicidal ideation, intent, or plan",
"     </li>",
"     <li>",
"      Access to means for suicide and the lethality of those means",
"     </li>",
"     <li>",
"      Presence of psychotic symptoms, command hallucinations, or severe anxiety",
"     </li>",
"     <li>",
"      Presence of alcohol or substance use",
"     </li>",
"     <li>",
"      History and seriousness of previous attempts",
"     </li>",
"     <li>",
"      Family history of or recent exposure to suicide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation in an emergency department",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hospitalization should be considered for patients at significant risk of suicide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are felt to have severe depression (eg, significant distress or decrease in function), whether or not they are suicidal, should be referred to a psychiatrist for management. Indications for referral, and possible hospitalization, include patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant suicidal ideation in whom outpatient safety cannot be assured",
"     </li>",
"     <li>",
"      Significant weight loss or severe psychomotor retardation or agitation",
"     </li>",
"     <li>",
"      Intent to harm others",
"     </li>",
"     <li>",
"      Psychotic features, ie, delusions or hallucinations",
"     </li>",
"     <li>",
"      Depression, who need treatment for substance abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unipolar major depression with psychotic features is often accompanied by suicidal ideation and suicide attempts, as well as comorbid anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The epidemiology, clinical features, assessment, diagnosis, treatment, and prognosis of unipolar psychotic depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5368?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electroconvulsive therapy should be considered as an initial treatment for life-threatening depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41416?source=see_link\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment tool",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nine-item Patient Health Questionnaire (PHQ-9) is a self-report, standardized, depression rating scale that can be used to diagnose major depression and measure its severity (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It can also be used for measurement based care to ascertain response to treatment (medication or psychotherapy). A score of &gt;20 on the PHQ-9 indicates severe depression, whereas a score &lt;6 indicates remission. A decrease &ge; 50 percent indicates a significant clinical response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Discussing diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients, especially those seen in primary care, often are reluctant to accept a diagnosis of depression. It may be helpful to stress the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression is common.",
"     </li>",
"     <li>",
"      Depression is associated with both emotional symptoms (mood changes) and physical symptoms (ie, fatigue, headache, abdominal pain, muscle tension). Depression increases both the perception and impact of physical symptoms.",
"     </li>",
"     <li>",
"      Depression is a physical illness, associated with biologic changes in neurochemistry in the brain.",
"     </li>",
"     <li>",
"      Treatment with medication",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychotherapy generally shortens the course of depression and diminishes symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Reluctant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless there is a concern for suicidality, patients who are uncomfortable with a diagnosis of depression can initially be observed with short-term follow-up (eg, two weeks) arranged. A patient diary that records sleep, mood, appetite, and concentration difficulties during this period may be useful in encouraging patients to accept treatment. Framing medication trials or counseling as having diagnostic value for depression may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adherence to medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who will be treated with medication should be told the following, at the initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not stop medications without talking with the prescribing clinician",
"     </li>",
"     <li>",
"      There may be a lag of two to three weeks before medications begin to relieve symptoms",
"     </li>",
"     <li>",
"      Early side effects, such as nervousness, headache and stomach upset, occur frequently during the first few days, but are predictably gone within a week of starting the medication",
"     </li>",
"     <li>",
"      It is important to continue a full course of antidepressant therapy (usually 6 to 12 months), even if symptoms are alleviated in the first month, to prevent early relapse",
"     </li>",
"     <li>",
"      Call to discuss side effects or other questions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite evidence of an increased risk of relapse if medication is discontinued prematurely, one study indicated that 42 percent of patients had discontinued their antidepressant by 30 days and 72 percent by 90 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/18\">",
"     18",
"    </a>",
"    ]. Half of these patients discontinued medications because they felt better, and believed medications could be taken as needed thereafter. Patients were more likely to discontinue medication or miss doses regularly if they were reluctant to initiate medication, experienced unanticipated side effects, or didn't recall being told that their medication needed to be continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regularly scheduled office visits, especially upon medication initiation, may improve medication continuation and allow monitoring and adjustment for side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lifestyle advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be encouraged to engage in exercise and positive activities (\"behavioral activation\") that may have been stopped due to depression. However, exercise alone is not an effective treatment strategy for most patients with major depression (see",
"    <a class=\"local\" href=\"#H48\">",
"     'Exercise'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Relaxation techniques may be tried for patients with minimal symptoms. A meta-analysis of 11 trials found that relaxation reduced self-reported symptoms compared to no treatment, but was not as effective as psychological treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the modality of treatment selected for initial therapy, the goal of treatment should be symptom remission. The STAR*D trial, conducted in 18 primary care and 23 outpatient psychiatry practices, is a large study of sequential treatment strategies in a representative sample of outpatients with nonpsychotic major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The randomized trial was designed to compare long term outcomes of various treatments, and to determine patient characteristics that might predict selective response to one treatment over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall findings include the recognition that patients who experienced clinical remission had a better long-term prognosis than patients with partial response, but that there was reluctance on the part of clinicians and patients to push treatment towards full remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy, alone or in combination with antidepressant medication, is an option for patients with mild to moderate major depression. A review of 12 psychotherapy trials completed in primary care found that depression-specific psychotherapies produced outcomes similar to pharmacotherapy and better than usual primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/23\">",
"     23",
"    </a>",
"    ]. Patient preference and insurance coverage may influence the decision for psychotherapy.",
"   </p>",
"   <p>",
"    Patients who do not respond after twelve weeks of initial psychotherapy should be started on an antidepressant, as part of a combined treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/24\">",
"     24",
"    </a>",
"    ]. Starting antidepressants earlier than twelve weeks may be considered as well, because many patients do not optimally benefit from psychotherapy without a concurrent antidepressant. Patients with severe, chronic (more than two years), or recurrent depression should be treated with a combination of pharmacotherapy and psychotherapy.",
"   </p>",
"   <p>",
"    A broad range of psychological interventions appear to be effective for the treatment of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. The Depression Guideline Panel of the Agency for Health Care Policy and Research (AHCPR) concluded that for patients with major depression, the efficacy of cognitive therapy, behavioral therapy, and interpersonal therapy was 46, 55, and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/26\">",
"     26",
"    </a>",
"    ]. Family and couples therapy, psychodynamic psychotherapy, and problem-solving therapy are also effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. In addition, mindfulness-based cognitive therapy may possibly delay or prevent recurrence of major depression as effectively as medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Interpersonal psychotherapy also appears to prevent recurrence of major depression, but not as effectively as medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18025?source=see_link\">",
"     \"Family and couples therapy for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28328?source=see_link\">",
"     \"Depression in adults: Psychodynamic psychotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8584?source=see_link\">",
"     \"Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2007 representative survey of the United States general population found that among outpatients treated for unipolar depressive disorders, the proportion using psychotherapy alone was 6 percent, and the proportion using psychotherapy plus pharmacotherapy was 43 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/35\">",
"     35",
"    </a>",
"    ]. These percentages are conservative estimates, because they do not include patients treated for an adjustment disorder, many if not most of whom were probably suffering from a depressive syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY VERSUS PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy and manual-based psychotherapy are each efficacious for treating depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/36\">",
"     36",
"    </a>",
"    ]. Multiple randomized trials of patients in the primary care setting have found similar efficacy for each treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/5,28,29\">",
"     5,28,29",
"    </a>",
"    ], with no clear predictors of which treatment is best for individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the National Institute for Clinical Excellence (NICE) in the United Kingdom recommend psychotherapy as initial treatment for patients with mild depression, citing that the risk benefit ratio does not warrant pharmacotherapy for mild symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/38\">",
"     38",
"    </a>",
"    ]. The AHCPR Guideline Panel recommends drug therapy alone as the initial treatment for severely depressed patients, and either medication or psychotherapy for mild or moderate depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/26\">",
"     26",
"    </a>",
"    ]. The panel notes the importance of regular follow-up for patients treated with medication to assure compliance, assess response, and develop a supportive relationship with their clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 12 randomized trials comparing antidepressant treatment alone with antidepressant treatment combined with psychotherapy found a higher response rate for patients in the combination group (OR 1.86, 95% CI 1.38-2.52); the severity or chronicity of depression was not noted in this review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined treatment is both more costly and time consuming. An earlier meta-analysis comparing psychotherapy alone with antidepressant plus psychotherapy found no significant difference in response rates for mild depression, but significantly increased response to combination therapy for more severe and recurrent depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/40\">",
"     40",
"    </a>",
"    ]. Most data favor combination therapy for patients with severe, chronic (more than two years) or recurrent symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/12,41\">",
"     12,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major classes of drugs used to treat depression are considered \"first generation\" (monoamine oxidase inhibitors [MAOIs], and tricyclic antidepressants [TCAs]) and \"second generation\" (selective serotonin reuptake inhibitors [SSRIs], inhibitors of the reuptake of both serotonin and norepinephrine [SNRIs], and a few drugs with unique modes of action) (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants are beneficial for patients with unipolar major depression. In a meta-analysis of patient level data from 37 randomized trials (8477 patients with major depression) that compared either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (modal dose 20 mg per day) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (modal dose range 75 to 150 mg per day) with placebo for six weeks, the primary findings included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission occurred in more patients who received active drug than placebo (43 versus 29 percent)",
"     </li>",
"     <li>",
"      Response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in more patients who received active treatment than placebo (58 versus 40 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with acute major depression in the primary care setting, antidepressants are associated with a 50 to 60 percent response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/27,43\">",
"     27,43",
"    </a>",
"    ]. In one multicenter \"real-world\" study (N = 2876 outpatients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ), remission occurred in 28 percent, with a mean time to remission of seven weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Publication bias should be considered in evaluating the literature regarding antidepressant trials. A 2008 meta-analysis of second generation antidepressants found that 69 percent of the 203 trials meeting inclusion criteria were supported by pharmaceutical companies, 9 percent by governmental or independent sponsors, and the funding source was not identifiable for 22 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/45\">",
"     45",
"    </a>",
"    ]. In a study comparing published antidepressant drug trials with drug trials registered with the FDA, 94 percent of published trials reported positive results, compared with 51 percent of trials tracked by the FDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, as with other drugs, published trials of antidepressants are likely to show a greater effect size than may be actually present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13163623\">",
"    <span class=\"h3\">",
"     Mild major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants appear to be efficacious for unipolar major depression regardless of baseline severity, including patients with mild major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/42\">",
"     42",
"    </a>",
"    ]. The belief that pharmacotherapy benefits only severely ill patients stems in part from a meta-analysis of six randomized trials (718 patients, nearly all with major depression) that compared antidepressants with placebo; results suggested a substantial benefit in very severe depression and little or no benefit in mild to moderate depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/47\">",
"     47",
"    </a>",
"    ]. However, a subsequent, larger meta-analysis of 37 randomized trials (8477 patients with major depression) that compared antidepressants with placebo found that remission at six weeks occurred in more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mildly ill patients who received active drug than placebo (50 versus 37 percent) &nbsp;",
"     </li>",
"     <li>",
"      Severely ill patients who received active drug than placebo (38 versus 25 percent) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences may underestimate antidepressant effects over longer time periods.",
"   </p>",
"   <p>",
"    Although the larger meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/42\">",
"     42",
"    </a>",
"    ] is more believable than the earlier one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/47\">",
"     47",
"    </a>",
"    ] and we are confident that antidepressants are efficacious for unipolar major depression of mild severity, nevertheless, there are hundreds of other randomized trials that were not included in the two meta-analyses. An analysis that included these other trials would provide a better basis for evaluating the efficacy of pharmacotherapy in mild major depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Choice of antidepressant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most systematic reviews have concluded that clinical and quality of life outcomes, as well as overall treatment costs, provide no clear guidance on the choice among specific antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/43,48-51\">",
"     43,48-51",
"    </a>",
"    ]. As an example, a meta-analysis of 93 randomized trials (&gt;20,000 patients with unipolar major depression) found treatment effects among second-generation antidepressants were comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/52\">",
"     52",
"    </a>",
"    ]. However, results from these systematic reviews are limited to acute treatment (6 to 12 weeks), and thus do not address long-term outcomes and cumulative side effects.",
"   </p>",
"   <p>",
"    The choice of antidepressant is likely to be less important than treating patients with medications that they can tolerate, and with doses sufficient to achieve symptom remission.",
"   </p>",
"   <p>",
"    SSRIs are often first line in primary care because they cause fewer side effects than other drugs and are less dangerous with overdose. The 2008 clinical practice guidelines from the American College of Physicians (ACP) make a strong recommendation to initiate one of 12 second-generation antidepressants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ), based on their similar efficacy and side effect profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/53\">",
"     53",
"    </a>",
"    ]. We do not recommend use of nefazodone, however, due to its hepatotoxicity.",
"   </p>",
"   <p>",
"    Multiple meta-analyses have evaluated comparisons of antidepressant medications. Findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The guidelines for the ACP were based on a meta-analysis of 203 randomized trials comparing efficacy and effectiveness of 12 second generation antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/53\">",
"       53",
"      </a>",
"      ]. Most trials compared drugs with placebo and 70 percent were supported by pharmaceutical companies. Drugs were similar in regard to acute and maintenance phase response rates, impact on quality of life indices, and treatment response for associated symptoms (anxiety, insomnia, pain) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/45\">",
"       45",
"      </a>",
"      ]. Small effect size differences were not considered to be clinically relevant.",
"     </li>",
"     <li>",
"      Another meta-analysis included 117 randomized trials in which two or more of the following 12 second-generation antidepressants, used as monotherapy, were evaluated:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , reboxetine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/54\">",
"       54",
"      </a>",
"      ]. In the absence of head-to-head drug trials, multiple treatment (network) meta-analysis was used to compare two dichotomous outcomes (response, defined as &gt;50 percent improvement in symptom score; and patient drop out during treatment). Escitalopram and sertraline showed the best combined profile of acceptability and efficacy. Methodological concerns with indirect comparisons (including heterogeneity in patient populations and comparability of drug doses), pharmaceutical sponsorship of most trials, and inadequate reporting of randomization techniques or allocation concealment may limit the validity of these findings. In addition, it is unclear whether the differences between drugs were clinically meaningful or would be sustained beyond the eight week-average study period.",
"     </li>",
"     <li>",
"      Two meta-analyses evaluated randomized trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/55\">",
"       55",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/56\">",
"       56",
"      </a>",
"      ] versus other antidepressive agents. The studies found both sertraline and escitalopram more effective than the comparator drugs, although it is uncertain if differences were clinically significant.",
"     </li>",
"     <li>",
"      In a meta-analysis of 28 randomized, controlled trials involving 5940 primary care patients with major depression, dysthymia, or mixed anxiety depression, newer antidepressants (including selective serotonin reuptake inhibitors,",
"      <span class=\"nowrap\">",
"       serotonin/norepinephrine",
"      </span>",
"      reuptake inhibitors, reversible inhibitors of monoamine oxidase, and dopamine antagonists) resulted in higher rates of response than placebo (RR 1.6, 95% CI 1.2-2.1), but rates were similar to those for tricyclic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of 55 randomized, controlled trials of MAO inhibitors versus tricyclic antidepressants found that MAO inhibitors were less effective for severe depressive disorders but possibly more effective in atypical depressive disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of 46 randomized controlled trials and 24 observational studies of head-to-head comparisons between second-generation antidepressants (SSRIs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) concluded that there were no significant differences in efficacy or tolerability among these drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/58\">",
"       58",
"      </a>",
"      ]. By contrast, a meta-analysis of 12 randomized trials (2626 patients with major depression) found that response occurred in significantly more patients who received mirtazapine than an SSRI (OR 1.2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is limited evidence that tricyclics may be preferred for more severely depressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/60\">",
"     60",
"    </a>",
"    ]. A meta-analysis of 25 randomized controlled trials for treatment of hospitalized, depressed patients found tricyclics were significantly more efficacious compared to SSRIs, but the clinical difference was small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/61\">",
"     61",
"    </a>",
"    ]. The role of tricyclic antidepressants in treating major depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link&amp;anchor=H3#H3\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Role in treating depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/26\">",
"     26",
"    </a>",
"    ]. A positive response to a particular antidepressant by a first degree relative may be another factor to consider. Some meta-analyses suggest small differences in clinical efficacy that are unlikely to have clinical relevance. Since efficacy differences are not a clinically important issue, other factors to be considered in drug selection include physician familiarity, cost, formulary preference, and side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous drug-drug interactions may occur with antidepressant use, involving concurrent use of more than one antidepressant, or other types of medication. Prior to prescribing an antidepressant, potential interactions with a patient's preexisting medication regimen should be checked using the drug interaction database available through UpToDate or in other programs.",
"   </p>",
"   <p>",
"    Specific antidepressants may cause more weight gain than others. A systematic review of second-generation antidepressants evaluated 203 studies and found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    were associated more weight gain than other drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related issue is the risk of diabetes. It appears that depression itself is a risk factor for developing diabetes. A cohort study of 1000 people 65 years and older, followed prospectively for up to ten years, found that depressed individuals were more than twice as likely to develop diabetes compared to those without depression, regardless of antidepressant treatment (hazard ratio 2.3, 95% CI 1.3-4.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, specific antidepressants or antidepressants as a class of medications may possibly be associated with an increased risk of diabetes. A nested case-control study found that among approximately 166,000 patients with depression and no sign of diabetes, long-term use (&gt;24 months) of an antidepressant in moderate to high doses was associated with a significantly increased risk of diabetes (incidence rate ratio 1.8, 95% CI 1.4-2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/63\">",
"     63",
"    </a>",
"    ]. Analysis of individual antidepressants found an increased risk estimate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (incidence rate ratio: 1.43, 1.03-1.98),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    (incidence rate ratio: 4.91, 1.05-23.03),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (incidence rate ratio: 1.33, 1.02-1.73), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (incidence rate ratio: 2.03, 1.18-3.48).",
"   </p>",
"   <p>",
"    A study using a claims data base found an association between antidepressants and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/64\">",
"     64",
"    </a>",
"    ]. Problems with the study, including confounds and the possibility of reverse causality, lead us to suggest that clinicians should not change their practice with regard to this issue until better designed studies have been conducted. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SSRIs tend to have similar side effect profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/65\">",
"     65",
"    </a>",
"    ]. However, certain SSRIs may be more likely to cause specific side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/66\">",
"     66",
"    </a>",
"    ]. Thus, some patients who cannot tolerate one SSRI may do well with another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/67\">",
"     67",
"    </a>",
"    ]. Side effects of SSRIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link&amp;anchor=H399779851#H399779851\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     SNRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;SNRIs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    ) have many similar side effects to SSRIs because of the serotonergic effect of these medications. These side effects include jitteriness, restlessness, headache, insomnia and sexual side effects, particularly delayed orgasm. SNRIs also have noradrenergic side effects, particularly at high dosages, including increased sweating and dizziness. Venlafaxine may cause hypertension at dosages of 300 mg or greater. Potentially lethal cardiac effects have been reported with overdose of venlafaxine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/68\">",
"     68",
"    </a>",
"    ]. Duloxetine may slightly impair glycemic control in patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/69\">",
"     69",
"    </a>",
"    ], and has been associated with fatal liver failure in patients with preexisting liver disease and is contraindicated in this subgroup of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Tricyclic and tetracyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of cyclic antidepressants include dry mouth, blurred vision, constipation, urinary retention, tachycardia, and confusion or delirium. These are the result of anticholinergic activity. The elderly are particularly susceptible to memory impairment, confusion, and hallucinations. Side effects of tricyclic and tetracyclic antidepressants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link&amp;anchor=H19#H19\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     MAO inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAO inhibitors are often avoided because of their potential to precipitate enhanced sympathetic activity and severe hypertension with the concomitant ingestion of tyramine-containing foods (eg, fermented cheeses, imported beer, Chianti, champagne, some other wines, soy sauce, avocados, bananas, overripe or spoiled food, and any fermented, smoked, or aged fish or meat). The hypertensive reaction is dose-dependent and can be exacerbated if the patient is also taking a sympathomimetic drug.",
"   </p>",
"   <p>",
"    MAO inhibitors are best managed by specialists with experience in prescribing these medications, and are not considered to be first-line therapy for depressed patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      has significantly fewer adverse effects related to sexual dysfunction than SSRIs, and may be particularly effective for patients who are lethargic. Additionally, bupropion is not associated with weight gain.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       Mirtazapine",
"      </a>",
"      , a mixed serotonin-norepinephrine antagonist, is sedating. It has efficacy equivalent to SSRIs and may have a role in the treatment of patients with insomnia and depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/70\">",
"       70",
"      </a>",
"      ]. Mirtazapine causes more weight gain than SSRIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/58,70\">",
"       58,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"       Nefazodone",
"      </a>",
"      has been associated with fatal liver failure and is no longer available in several countries.",
"     </li>",
"     <li>",
"      Agomelatine does not appear to cause sexual side effects or weight gain, but may elevate serum transaminase levels more than three times the upper limit of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacology, dosing, and adverse effects of these medications are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Dosage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Starting at low doses can minimize the side effects of antidepressants. Typical starting doses are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ), but even lower doses may minimize side effects, particularly in the elderly. For the SSRIs, for example, it is reasonable to initially prescribe 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , 5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , or 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    for approximately one week, and gradually titrate up to full doses. The drugs are usually taken in the morning; they can be mildly stimulating for the first 8 to 12 hours after oral ingestion and may disturb sleep.",
"   </p>",
"   <p>",
"    Doses of SSRIs that are higher than typical may be necessary to achieve remission. In the Sequential Treatment Alternatives to Relieve Depression trial (STAR*D) involving outpatient treatment for 2876 patients with major depression, 80 percent of whom had chronic depression with recurrent episodes, the average dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    needed to achieve remission was 42 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the United States Food and Drug Administration issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose should not exceed 40 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lower doses of tricyclic antidepressants may work as well as higher doses. A meta-analysis of 35 studies (2013 patients) concluded that doses equivalent to &le;100 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    were as effective as higher doses, and both were more effective than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Timing of response and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to be monitored (by phone or visit) at least every one to two weeks for six to eight weeks during the initiation phase of new pharmacologic treatment. The AHCPR Panel recommended that more severely depressed patients be seen at least twice a month for supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/26\">",
"     26",
"    </a>",
"    ]. The PHQ-9 tool may be used to assess depression response over time (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lag time before an initial therapeutic response to antidepressant therapy is observed has been thought to be two to six weeks. However, a meta-analysis of 50 placebo-controlled randomized trials found that about one-third of the maximal therapeutic response is observed after the first week of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/76\">",
"     76",
"    </a>",
"    ]. Two industry-sponsored trials found that early treatment response (within two weeks) predicts likelihood of achieving a stable response and sustained remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment time to maximal response may be six weeks or longer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 182 outpatients with major depression who had a sustained acute response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      therapy, the probability of response was 56 percent at two weeks, 81 percent at four weeks, and 90 percent at six weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/79\">",
"       79",
"      </a>",
"      ]. Thus, more than half of eventual responders begin to respond by week two.",
"     </li>",
"     <li>",
"      In the multicenter STAR*D trial, 56 percent of those who responded (more than 50 percent improvement) did so at or after eight weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/44\">",
"       44",
"      </a>",
"      ]. More than 80 percent of this population had chronic depression with relapsing episodes. The mean time to achieve response was 5.7 weeks and the mean treatment time to remission was 6.7 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy should be modified if the response to an initial medication is inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/53\">",
"     53",
"    </a>",
"    ]. Dosages should be increased if there is lack of response after two weeks. If there is no response by 8 to 10 weeks at a maximum therapeutic dose, the patient should be given a trial of another antidepressant (either of the same or different class) or should be referred to a psychiatrist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/50\">",
"     50",
"    </a>",
"    ]. For partial responders, patients may be augmented with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , or changed to another SSRI, SNRI, or bupropion if they prefer not to be on a second antidepressant. Although the data are limited, approximately one-third of patients may respond to a second antidepressant trial (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. After two SSRIs have been ineffective, antidepressants from a different class (such as bupropion or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) should be chosen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adherence may be further enhanced by facilitating telephone access to the clinician for patient questions about side effects. Outcomes and adherence can also be improved with the use of allied health professionals to proactively check on therapeutic response, side effects, and adherence, and to schedule return visits for patients with persistent symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation treatment is generally indicated for patients who respond to acute treatment of unipolar major depression, and additional maintenance treatment is indicated for patients with an increased risk of recurrence. Continuation and maintenance treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=see_link\">",
"     \"Unipolar depression in adults: Continuation and maintenance treatment\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the medications used in augmentation therapy for resistant depression may also be appropriate for consideration earlier in therapy in specific patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .) These patients are most appropriately treated by a psychiatrist who can collaborate with the primary care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive treatment with the second-generation antipsychotics",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is efficacious for unipolar, nonpsychotic major depression that has not responded to antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/83\">",
"     83",
"    </a>",
"    ]. Augmentation of antidepressants with second-generation antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mood stabilizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mood swings and a strong family history of bipolar disorder may meet criteria for bipolar II disorder, and should be treated with a mood stabilizing drug such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    monotherapy may effectively treat acute unipolar depression, but there is far less evidence than there is for antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. We do not suggest using lithium as first-, second-, or third-line treatment for acute unipolar depression. Use of lithium to treat unipolar depression is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Anxiolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiolytics can be used as adjunctive treatment with an antidepressant for major depression that includes symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation. The indications, general principles, and specific anxiolytic drug options are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/3/17464?source=see_link\">",
"     \"Unipolar depression in adults: Anxiolytics\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Treatment for anxiety disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     St. John's wort",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for St. John's wort (hypericum extract) in the treatment of depression is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=see_link\">",
"     \"Clinical use of St. John's wort\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, European studies of well-defined standardized extracts of St. John's wort suggest that it is more effective than placebo and equivalent to tricyclic antidepressants and SSRIs in the short-term treatment of depression. However, studies in the US do not support its efficacy in the treatment of severe depression, and further research in mild depression is ongoing. A systematic review notes the different findings depending on country of origin, but concludes that treatment with hypericum extract is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mild acute depression can be offered St. John's wort as an alternative to psychotherapy or conventional pharmacotherapy. In the absence of more consistent evidence, we suggest that St. John's wort not be used in patients with significant major depression.",
"   </p>",
"   <p>",
"    We suggest avoiding concurrent use of St. John's wort and other antidepressants. Concomitant use with the selective serotonin reuptake inhibitors (SSRIs) may lead to the \"serotonin syndrome,\" characterized by agitation, hyperthermia, diaphoresis, tachycardia, and neuromuscular disturbances including rigidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    St. John's wort also has potentially important drug interactions with a number of medications including HIV protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of St. John's wort\", section on 'Herb-drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychostimulants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , methylamphetamine, and pemoline) and a novel acting agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    , have been evaluated for both the initial treatment of depression as well as for use as adjunctive therapy in the treatment of resistant depression. A 2008 systematic review of short-term studies (four weeks) found that psychostimulating agents, compared to placebo, were somewhat effective for initial treatment of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/89\">",
"     89",
"    </a>",
"    ]. One study found no difference in symptoms, comparing with treatment with modafinil or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/90\">",
"     90",
"    </a>",
"    ]. The individual studies were small and there is question whether the difference in outcomes was clinically significant. Larger trials with longer follow-up are indicated before these medications can be recommended for initial depression treatment outside of a study setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Antiglucocorticoid treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     DHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral supplementation with the adrenal androgen dehydroepiandrosterone (DHEA) may be of some benefit in patients with depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In a six week crossover trial in 46 patients with major or minor depression who were not treated with an antidepressant medication, patients had significantly lower depression scores while receiving DHEA (30 mg three times daily for three weeks followed by 150 mg three times daily for three weeks) than at baseline or while receiving placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/92\">",
"     92",
"    </a>",
"    ]. Androgenic side effects were not noted in this study.",
"   </p>",
"   <p>",
"    There is limited evidence on the safety or long-term effectiveness of DHEA and we do not currently recommend it for the treatment of depression. Acne and hirsutism have both been described in women participating in longer-term trials of DHEA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antiglucocorticoid treatments have also been evaluated for depression. A meta-analysis of five trials in patients with non-psychotic depression found that treatment with one of several antiglucocorticoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , or DHEA), was associated with a significantly greater response compared to placebo (RR 0.72, 95% CI 0.56-0.91) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/93\">",
"     93",
"    </a>",
"    ]. The meta-analysis concluded that further investigation is indicated, given heterogeneity between studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Triiodothyronine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triiodothyronine (T3) has been used as augmentation therapy in patients with major depression who have not responded to initial treatment with antidepressant monotherapy, and has been combined with antidepressants at the onset of treatment to accelerate or enhance response (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27175?source=see_link\">",
"     \"Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21630324\">",
"    <span class=\"h2\">",
"     Creatine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatine may possibly be useful as short term, adjunctive treatment with antidepressants to treat unipolar major depression. An eight-week randomized trial compared creatine monohydrate (5 g per day) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    (10 to 20 mg per day) with placebo plus escitalopram in 52 women with unipolar major depression (mostly first episode) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/94\">",
"     94",
"    </a>",
"    ]. Exclusion criteria included comorbid renal disease and serum creatinine levels that exceeded the normal range (&gt;1.1",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Remission occurred in more patients who received adjunctive creatine than placebo (52 versus 26 percent). Adverse events were comparable for the two groups, and serum creatinine and blood urea nitrogen levels were within normal limits during the trial. However, this single trial needs to be replicated before we can suggest using adjunctive creatine routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Investigational drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential drug interventions for depression under investigation include substance P and antagonists of corticotropin releasing factors and glucocorticoid receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/95\">",
"     95",
"    </a>",
"    ]. Initial studies often involve animal models of depression, largely based on stress-induced depression that may not adequately simulate depression in human subjects, which is also dependent on genetic and environmental factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the STAR*D trial indicate that outcomes for initial therapy of depression are the same when identical care is provided either in primary care or psychiatric specialty settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/96\">",
"     96",
"    </a>",
"    ]. Clinical indicators that suggest the need for psychiatrist and other mental health specialist referral include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-line drug cannot be tolerated or produces no benefit",
"     </li>",
"     <li>",
"      Signs of severe depression with possible thought disorder or suicidal ideation are present",
"     </li>",
"     <li>",
"      Comorbid medical, psychiatric, or substance abuse disorders are present",
"     </li>",
"     <li>",
"      Patient wants to understand the depression and make significant behavioral and cognitive changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The psychiatrist may be more easily accepted by patients as an expert in psychopharmacology and neurochemistry. Close collaboration between the psychiatrist and primary care provider can reduce patient fears about being separated from or dismissed by the primary care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Collaborative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collaborative care programs that involve enhanced patient education, integration of psychiatric visits into primary care treatment, and use of non-physician mental health professionals or depression care managers can significantly enhance depression outcomes compared with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/97-107\">",
"     97-107",
"    </a>",
"    ]. A meta-analysis of 37 randomized controlled trials of collaborative care found effective programs were associated with three factors: improvement in medication adherence, use of a case manager with a mental health background, and regular case management supervision with a psychiatrist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/108\">",
"     108",
"    </a>",
"    ]. The intensity of patient contact within a collaborative care system is likely another important component of effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Confidentiality and liability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent presence of comorbid medical conditions, and interactions between antidepressant and other medications, require continued communication between psychiatric and primary care providers. Discrete descriptions of psychiatric symptoms, diagnosis, and treatment should be present in the medical record so that integration of care is possible.",
"   </p>",
"   <p>",
"    Insurance companies in the US commonly require medical chart access to review for \"medical necessity\" for mental health treatment. Medicare requires the presence of a treatment plan update that includes diagnosis, global assessment of function (GAF), treatment focus, length of treatment, type of medication, and nature of symptoms; updates are required every three months. Some basic principles will allow respect of patient confidentiality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make sure the patient is included within the sphere of communication. Patient permission is needed for written communication about their care; they should receive a copy of the communication.",
"     </li>",
"     <li>",
"      The medical record should be symptom-focused and treated as a working document shared by both patient and physician.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     MINOR DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management and treatment of minor depression are discussed separately (as are the clinical features and diagnosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35015?source=see_link\">",
"     \"Unipolar minor depression in adults: Management and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=see_link\">",
"     \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524936\">",
"    <span class=\"h1\">",
"     DYSTHYMIC DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysthymic disorder is characterized by dysphoria and other depressive symptoms lasting for at least two years; however, symptoms are not as numerous as in major depression. Diagnosis of dysthymic disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Dysthymic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antidepressants are effective for dysthymic disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 9 randomized trials (1454 patients with dysthymia treated for an average of 10 weeks) found that response (reduction of baseline symptoms &ge;50 percent) occurred in more patients who received an antidepressant than placebo (52 versus 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/110\">",
"       110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of 20 randomized trials (2918 patients with depression lasting at least two years; most patients were diagnosed with dysthymia) compared selective serotonin reuptake inhibitors (SSRIs) with placebo, tricyclic antidepressants with placebo, and SSRIs with tricyclics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/111\">",
"       111",
"      </a>",
"      ]. Treatment duration ranged from 4 to 12 weeks. Remission was greater with SSRIs or tricyclics than with placebo, and was comparable for SSRIs and tricyclics. However, discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, psychotherapy does not appear to be useful for treating the symptoms of dysthymic disorder. A review of randomized trials found little to no benefit for a variety of therapies, including dynamic therapy, interpersonal psychotherapy, cognitive-behavioral therapy, and behavior therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/112\">",
"     112",
"    </a>",
"    ]. The trials that have examined the use of interpersonal therapy in dysthymic disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=see_link&amp;anchor=H2291390#H2291390\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Dysthymic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of depression in older adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision how best to treat depression in pregnant women is complex and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29735?source=see_link\">",
"     \"Depression in pregnant women: Clinical features and consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other drug use during pregnancy, the decision to treat depressed women with pharmacotherapy depends upon a balance of risks and benefits; there may be some adverse effects of drugs on the fetus, yet allowing a woman to suffer with symptomatic depression during pregnancy can also result in unacceptable costs to the woman and fetus.",
"   </p>",
"   <p>",
"    The balance of evidence suggests that mild to moderately depressed pregnant patients should be treated with psychotherapy. Severely depressed pregnant patients and those not responding to psychotherapy should, in addition, receive pharmacotherapy. Although several studies have demonstrated normal pregnancy outcomes with the use of tricyclic antidepressants or SSRIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/113-115\">",
"     113-115",
"    </a>",
"    ], first trimester use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    has been associated with an increased risk of major congenital defects and carries a warning label cautioning use in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29735?source=see_link\">",
"     \"Depression in pregnant women: Clinical features and consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Depression in medical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression in patients with general medical illnesses is common and an important cause of morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/5,118\">",
"     5,118",
"    </a>",
"    ]. Depression in patients with chronic medical illness is associated with increased physical symptoms; functional impairment; poor adherence to diet, exercise, and medications; and increased medical costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/5\">",
"     5",
"    </a>",
"    ]. Depression is also associated with worse outcomes of conditions including stroke, myocardial infarction, and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/119-123\">",
"     119-123",
"    </a>",
"    ]. Additionally, there is evidence that depression may increase the risk of developing such diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of depression in the physically ill is complex; symptoms such as a low mood and lack of energy may be due to the physical illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to depression. Depression associated with specific medical conditions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12504?source=see_link\">",
"     \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/3/11322?source=see_link\">",
"     \"Psychiatric illness in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While treatment of depression in patients with general medical illnesses improves depression, it is unclear whether such treatment improves general medical outcomes, because of conflicting results across multiple studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/99,100,121,124-129\">",
"     99,100,121,124-129",
"    </a>",
"    ]. As an example, a 12 month, single-blind, randomized trial enrolled 214 patients with depression and poorly controlled diabetes, coronary heart disease, or both, and compared treatment as usual with collaborative care, in which a medically supervised nurse provided guideline-based care for managing depression and the medical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/130\">",
"     130",
"    </a>",
"    ]. Improvement of glycated hemoglobin levels, low-density lipoprotein (LDL) cholesterol, and systolic blood-pressure levels, as well as depressive symptoms, was greater with collaborative care. By contrast, other studies have found that treating depression after acute coronary syndromes does not improve mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. Improvement in general medical outcomes may thus depend upon the specific intervention that is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351404\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants are effective for depression and safe in patients with general medical illnesses, based upon many randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 18 trials (838 depressed patients with a variety of physical diseases), antidepressants resulted in greater improvement in depressive symptoms than either placebo or no therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/133\">",
"       133",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of 25 trials (2338 patients with unipolar major depression and various comorbid general medical illnesses) found that response (50 percent or more reduction in baseline depression symptoms) occurred in more patients who received an antidepressant compared with placebo (risk ratio 1.4, 95% CI 1.3-1.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/134\">",
"       134",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of seven trials compared antidepressants (primarily selective serotonin reuptake inhibitors) with placebo in 306 patients with depression and diabetes mellitus, and found a clinically moderate benefit favoring antidepressants; heterogeneity across studies was moderate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/129\">",
"       129",
"      </a>",
"      ]. In addition, glycemic control was superior in patients who received antidepressants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large trials have also found that antidepressants are effective in patients with coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    have been shown to reduce neuropathic pain in patients without depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/136-138\">",
"     136-138",
"    </a>",
"    ], and are preferred drug choices in depressed patients with chronic pain to both alleviate pain symptoms and treat the underlying depression. A 12 week randomized trial compared usual care with a stepped care approach of initial optimization of antidepressant treatment followed by a supervised pain self-management program in 250 patients with concurrent depression and musculoskeletal pain; improvement of both depression and pain at 6 and 12 month follow-up were greater with stepped care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/139\">",
"     139",
"    </a>",
"    ]. In this trial, venlafaxine was used in 61 percent of the intervention patients, an SSRI in 32 percent, and other antidepressants or combinations in the remainder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92061287\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with chronic medical illnesses, exercise can reduce depressive symptoms. A meta-analysis of 90 randomized trials examined the effects of exercise training on depressive symptoms (which did not meet criteria for a depressive disorder) in 10,534 patients with chronic medical illnesses such as cardiovascular disease, chronic pain and fibromyalgia, cancer, spinal cord injury, multiple sclerosis, and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/140\">",
"     140",
"    </a>",
"    ]. Exercise led to a statistically significant but clinically modest reduction of depressive symptoms. However, in our clinical experience, many depressed patients with medical illnesses will not accept an exercise intervention due to fatigue, lack of motivation, or problems ambulating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     OTHER TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies with methodologic flaws suggest that aerobic exercise is superior to no treatment for patients with major depression.",
"   </p>",
"   <p>",
"    A meta-analysis of 25 randomized trials evaluating exercise, compared to standard treatment or no treatment, in patients with depression found that most trials did not analyze by intention to treat, and used inadequate randomization techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/141\">",
"     141",
"    </a>",
"    ]. A moderate but nonsignificant effect of exercise was seen when three higher quality studies were analyzed, although a large clinical effect was found when all studies were included.",
"   </p>",
"   <p>",
"    One trial in older patients (age 50 and above) compared aerobic exercise (three supervised group aerobic exercise sessions per week), antidepressant therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ), or combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/142\">",
"     142",
"    </a>",
"    ]. Patients who received antidepressant therapy alone had the fastest initial response, but there was no difference between groups at 16 weeks or 10 months. The patients who volunteered for the study were motivated to exercise, highly educated, and relatively physically healthy, parameters that may be difficult to reproduce in the community setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature regarding the efficacy of light therapy is limited by design problems, including small sample sizes, inadequate blinding and placebo groups, and inconsistencies in the timing and dose of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22936?source=see_link&amp;anchor=H8#H8\">",
"     \"Seasonal affective disorder\", section on 'Light therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of randomized trials found that bright light therapy in nonseasonal depression was associated with a significant reduction in depression symptom severity with effect sizes similar to those in pharmacotherapy trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/8/40074/abstract/143\">",
"     143",
"    </a>",
"    ]. However, given the limitations of the underlying studies, additional research is needed with larger numbers of patients and longer follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=see_link\">",
"       \"Patient information: Depression (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/18/11554?source=see_link\">",
"       \"Patient information: When you have depression and another health problem (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/50/37664?source=see_link\">",
"       \"Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major depression is a treatable illness that responds to a variety of therapeutic interventions. Suicide is an uncommon complication of depression, but an assessment of suicide risk is critical in all depressed patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Suicidal ideation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment for depression should be remission of symptoms; partial response should result in incremental therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clear predictors whether psychotherapy or pharmacotherapy is best for individual patients with mild to moderate major depression. We recommend that patients with mild to moderate major depression begin either psychotherapy or pharmacotherapy as initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend pharmacotherapy as initial therapy for patients with more severe depression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend a combination of pharmacotherapy and psychotherapy for patients with severe chronic (more than two years) or frequently recurrent depression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pharmacotherapy versus psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major classes of drugs used to treat depression are the selective serotonin reuptake inhibitors (SSRIs), inhibitors of the reuptake of both serotonin and norepinephrine (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs) (",
"      <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"       table 2",
"      </a>",
"      ). Clinical and quality of life outcomes provide no clear guidance on the choice between these agents.",
"     </li>",
"     <li>",
"      Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs. Other factors to be considered in drug selection include physician familiarity, cost, formulary preference, and side effects (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"       table 3",
"      </a>",
"      ). Due to their greater potential for serious adverse effects, we recommend that monoamine oxidase inhibitors be restricted to patients who do not respond to other treatments (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Patients who require monoamine oxidase inhibitors are best managed by psychopharmacologists familiar with their use. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antidepressant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects of the antidepressants can be minimized by starting at low doses (",
"      <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"       table 2",
"      </a>",
"      ). Therapeutic doses may need to be decreased in the elderly. Antidepressants are usually taken in the morning to avoid sleep disturbance. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial therapeutic response typically occurs within two to six weeks of antidepressant therapy. We recommend that patients who have shown no response to antidepressant therapy by eight weeks be switched to another antidepressant (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that patients who show no response to a second antidepressant be referred to a psychiatrist for further medication adjustment or augmentation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that patients who have a partial response to an antidepressant at eight weeks be given options of either augmentation (with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      ) or change to another antidepressant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Timing of response and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients need to be evaluated at a minimum of every one to two weeks for six to eight weeks during the initiation phase of new pharmacologic treatment. This can be by office visit or telephone. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Timing of response and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuation treatment is generally indicated for patients who respond to acute treatment of unipolar major depression, and additional maintenance treatment is indicated for patients with an increased risk of recurrence. Continuation and maintenance treatment are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=see_link\">",
"       \"Unipolar depression in adults: Continuation and maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anxiolytics can be used as adjunctive treatment with an antidepressant for major depression that includes symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/3/17464?source=see_link\">",
"       \"Unipolar depression in adults: Anxiolytics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the inconsistent evidence for efficacy, and the lack of regulated standardized products proven to be efficacious, we suggest not treating depression with St. John's wort&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with mild acute depression who nonetheless choose St. John's wort as an alternative to psychotherapy or conventional pharmacotherapy should be advised that the combination of St. John's wort and other pharmaceutical antidepressants should be avoided. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'St. John's wort'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not advising exercise as a primary treatment for major depression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), although exercise may be a useful adjunct as part of behavioral activation. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. The World Health Report 22: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/2\">",
"      Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/3\">",
"      Barrett JE, Barrett JA, Oxman TE, Gerber PD. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988; 45:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/4\">",
"      Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/5\">",
"      Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/6\">",
"      Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/7\">",
"      Mann JJ. The medical management of depression. N Engl J Med 2005; 353:1819.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/9\">",
"      Smith DJ, Griffiths E, Kelly M, et al. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry 2011; 199:49.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Practice guideline for the treatment of major depressive disorder, third edition. Am J Psychiatry 2010; 167:10 (supplement).",
"    </li>",
"    <li>",
"     American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/12\">",
"      Fancher T, Kravitz R. In the clinic. Depression. Ann Intern Med 2007; 146:ITC5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/13\">",
"      Schaffer A, Flint AJ, Smith E, et al. Correlates of suicidality among patients with psychotic depression. Suicide Life Threat Behav 2008; 38:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/14\">",
"      Flint AJ, Peasley-Miklus C, Papademetriou E, et al. Effect of age on the frequency of anxiety disorders in major depression with psychotic features. Am J Geriatr Psychiatry 2010; 18:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/15\">",
"      Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/16\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/17\">",
"      Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/18\">",
"      Vos T, Haby MM, Barendregt JJ, et al. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/19\">",
"      Mitchell AJ. Depressed patients and treatment adherence. Lancet 2006; 367:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/20\">",
"      Jorm AF, Morgan AJ, Hetrick SE. Relaxation for depression. Cochrane Database Syst Rev 2008; :CD007142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/21\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/22\">",
"      Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/23\">",
"      Schulberg HC, Raue PJ, Rollman BL. The effectiveness of psychotherapy in treating depressive disorders in primary care practice: clinical and cost perspectives. Gen Hosp Psychiatry 2002; 24:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/24\">",
"      Dejesus RS, Vickers KS, Melin GJ, Williams MD. A system-based approach to depression management in primary care using the Patient Health Questionnaire-9. Mayo Clin Proc 2007; 82:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/25\">",
"      Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol Bull 1990; 108:30.",
"     </a>",
"    </li>",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression: Clinical Practice Guideline. US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR publication 93-0551, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/27\">",
"      Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/28\">",
"      Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995; 310:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/29\">",
"      Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/30\">",
"      Barbato A, D'Avanzo B. Marital therapy for depression. Cochrane Database Syst Rev 2006; :CD004188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/31\">",
"      Driessen E, Cuijpers P, de Maat SC, et al. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/32\">",
"      Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008; 76:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/33\">",
"      Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010; 67:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/34\">",
"      Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/35\">",
"      Olfson M, Marcus SC. National trends in outpatient psychotherapy. Am J Psychiatry 2010; 167:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/36\">",
"      Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012; 379:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/37\">",
"      Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med 1997; 27:731.",
"     </a>",
"    </li>",
"    <li>",
"     NICE. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: National Institute for Clinical Excellence 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/39\">",
"      Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/40\">",
"      Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/41\">",
"      Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006; 367:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/42\">",
"      Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/43\">",
"      Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/44\">",
"      Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/45\">",
"      Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/46\">",
"      Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/47\">",
"      Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/48\">",
"      Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/49\">",
"      Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/50\">",
"      Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000; 132:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/51\">",
"      Barbui C, Percudani M, Hotopf M. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies. J Clin Psychopharmacol 2003; 23:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/52\">",
"      Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011; 155:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/53\">",
"      Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/54\">",
"      Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/55\">",
"      Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; :CD006117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/56\">",
"      Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; :CD006532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/57\">",
"      Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/58\">",
"      Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/59\">",
"      Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011; :CD006528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/60\">",
"      Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/61\">",
"      Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/62\">",
"      Atlantis E, Browning C, Sims J, Kendig H. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010; 25:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/63\">",
"      Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/64\">",
"      Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011; 168:511.",
"     </a>",
"    </li>",
"    <li>",
"     Zahajszky, J, Rosenbaum, JF, Tollefson, GD. Fluoxetine. In: American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, American Psychiatric Publishing, Inc, Washington, DC 2009. p.289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/66\">",
"      Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008; 50:428.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate, LA, Fava, M, Rosenbaum, JF, et, al. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2010. p.54.",
"    </li>",
"    <li>",
"     Medicines and Healthcare Products Regulatory Agency. Updated prescribing advice for venlafaxine (Effexor/Effexor XL). www.mhra.gov.uk/home/idcpig?IdcService=GET_FILE&amp;dDocName=CON2023842&amp;RevisionSelectionMethod=LatestReleased (Accessed February 6, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/69\">",
"      Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/70\">",
"      Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008; 22:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/71\">",
"      McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/72\">",
"      Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 71:616.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/75\">",
"      Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/76\">",
"      Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/77\">",
"      Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 2009; 42:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/78\">",
"      Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/79\">",
"      Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423.",
"     </a>",
"    </li>",
"    <li>",
"     Evidence report/technology assessment: Number 7. Treatment of depression - Newer pharmacotherapies. Agency for Health Care Policy and Research, Rockville, MD, 1999. www.ahcpr.gov/clinic/ (Accessed 3/7/08).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/81\">",
"      Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/82\">",
"      Dietrich AJ, Oxman TE, Williams JW Jr, et al. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ 2004; 329:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/83\">",
"      Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/84\">",
"      Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 1987; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/85\">",
"      Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/86\">",
"      Linder J, Fyr&ouml; B, Pettersson U, Werner S. Acute antidepressant effect of lithium is associated with fluctuation of calcium and magnesium in plasma. A double-blind study on the antidepressant effect of lithium and clomipramine. Acta Psychiatr Scand 1989; 80:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/87\">",
"      Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; :CD000448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/88\">",
"      Hammerness P, Basch E, Ulbricht C, et al. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/89\">",
"      Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; :CD006722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/90\">",
"      Vaishnavi S, Gadde K, Alamy S, et al. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006; 26:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/91\">",
"      Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/92\">",
"      Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/93\">",
"      Gallagher P, Malik N, Newham J, et al. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008; :CD005168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/94\">",
"      Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012; 169:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/95\">",
"      Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/96\">",
"      Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 2008; 23:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/97\">",
"      Rost K, Nutting P, Smith J, et al. Improving depression outcomes in community primary care practice: a randomized trial of the quEST intervention. Quality Enhancement by Strategic Teaming. J Gen Intern Med 2001; 16:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/98\">",
"      Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/99\">",
"      Williams JW Jr, Katon W, Lin EH, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 2004; 140:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/100\">",
"      Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/101\">",
"      Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA 2004; 292:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/102\">",
"      Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/103\">",
"      Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/104\">",
"      Simon GE, VonKorff M, Rutter C, Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ 2000; 320:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/105\">",
"      Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA 2000; 283:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/106\">",
"      Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med 2000; 9:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/107\">",
"      Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med 2000; 9:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/108\">",
"      Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006; 166:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/109\">",
"      Dobscha SK, Corson K, Hickam DH, et al. Depression decision support in primary care: a cluster randomized trial. Ann Intern Med 2006; 145:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/110\">",
"      Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/111\">",
"      von Wolff A, H&ouml;lzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013; 144:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/112\">",
"      Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety 2010; 27:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/113\">",
"      Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/114\">",
"      Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/115\">",
"      Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159:2055.",
"     </a>",
"    </li>",
"    <li>",
"     file://ctr.gsk.co.uk/summary/paroxetine/epip083.pdf (accessed Dec 23, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/117\">",
"      Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005; 173:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/118\">",
"      Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005; 165:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/119\">",
"      Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry 2003; 48:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/120\">",
"      Barefoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996; 78:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/121\">",
"      Jackson JL, DeZee K, Berbano E. Can treating depression improve disease outcomes? Ann Intern Med 2004; 140:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/122\">",
"      Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 2003; 26:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/123\">",
"      Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/124\">",
"      Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/125\">",
"      Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/126\">",
"      Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 129:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/127\">",
"      Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/128\">",
"      Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/129\">",
"      Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev 2012; 12:CD008381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/130\">",
"      Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010; 363:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/131\">",
"      Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/132\">",
"      Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/133\">",
"      Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev 2000; :CD001312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/134\">",
"      Iovieno N, Tedeschini E, Ameral VE, et al. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol 2011; 26:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/135\">",
"      Lesp&eacute;rance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/136\">",
"      Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/137\">",
"      Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/138\">",
"      Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/139\">",
"      Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009; 301:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/140\">",
"      Herring MP, Puetz TW, O'Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/141\">",
"      Mead GE, Morley W, Campbell P, et al. Exercise for depression. Cochrane Database Syst Rev 2008; :CD004366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/142\">",
"      Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000; 62:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/8/40074/abstract/143\">",
"      Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162:656.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1725 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-220.255.2.146-317DDF55DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40074=[""].join("\n");
var outline_f39_8_40074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H51\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distinguishing unipolar and bipolar depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Suicidal ideation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Discussing diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Reluctant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adherence to medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lifestyle advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHARMACOTHERAPY VERSUS PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Combined therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13163623\">",
"      - Mild major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Choice of antidepressant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - SSRIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - SNRIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Tricyclic and tetracyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - MAO inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Dosage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Timing of response and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mood stabilizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Antiglucocorticoid treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - DHEA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Triiodothyronine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21630324\">",
"      Creatine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Investigational drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      PSYCHIATRIC CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Collaborative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Confidentiality and liability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      MINOR DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524936\">",
"      DYSTHYMIC DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Depression in medical illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351404\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92061287\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      OTHER TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Light therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1725|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/43/25278\" title=\"table 2\">",
"      Pharmacology antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38639\" title=\"table 3\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28328?source=related_link\">",
"      Depression in adults: Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29735?source=related_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12504?source=related_link\">",
"      Depression, mania, and schizophrenia in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18025?source=related_link\">",
"      Family and couples therapy for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8584?source=related_link\">",
"      Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/50/37664?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/18/11554?source=related_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/3/11322?source=related_link\">",
"      Psychiatric illness in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22936?source=related_link\">",
"      Seasonal affective disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/3/17464?source=related_link\">",
"      Unipolar depression in adults: Anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27175?source=related_link\">",
"      Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=related_link\">",
"      Unipolar depression in adults: Continuation and maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=related_link\">",
"      Unipolar major depression with psychotic features: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5368?source=related_link\">",
"      Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=related_link\">",
"      Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35015?source=related_link\">",
"      Unipolar minor depression in adults: Management and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_8_40075="Benefits pulmonary rehab COPD";
var content_f39_8_40075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benefits of pulmonary rehabilitation in COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Improves exercise capacity (",
"       <strong>",
"        Evidence A",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Reduces the perceived intensity of breathlessness (",
"       <strong>",
"        Evidence A",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Can improve health-related quality of life (",
"       <strong>",
"        Evidence A",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Reduces the number of hospitalizations and days in the hospital (",
"       <strong>",
"        Evidence A",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Reduces anxiety and depression associated with COPD (",
"       <strong>",
"        Evidence A",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Strength and endurance training of the upper limbs improves arm function (",
"       <strong>",
"        Evidence B",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Benefits extend well beyond the immediate period of training (",
"       <strong>",
"        Evidence B",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Improves survival (",
"       <strong>",
"        Evidence B",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Respiratory muscle training is beneficial, especially when combined with general exercise training (",
"       <strong>",
"        Evidence C",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychosocial intervention is helpful (",
"       <strong>",
"        Evidence C",
"       </strong>",
"       )",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Global Initiative for Chronic Obstructive Pulmonary Disease, based on an April 1998 meeting of the National Heart, Lung, and Blood Institute and the World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40075=[""].join("\n");
var outline_f39_8_40075=null;
var title_f39_8_40076="Immunoglobulin genes in B cells";
var content_f39_8_40076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunoglobulin (Ig) genes and protein expression during B cell development",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Antigen-independent phase",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Antigen-dependent phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pre-pro B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pro-B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pre B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Immature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Activated B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blast B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Memory B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plasma B cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surrogate light chain",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        <p>",
"         S + IgM",
"        </p>",
"        <p>",
"         H chain",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ig genes",
"       </td>",
"       <td>",
"        GL",
"       </td>",
"       <td>",
"        DJH",
"       </td>",
"       <td>",
"        VDJH",
"       </td>",
"       <td>",
"        <p>",
"         VJL",
"        </p>",
"        <p>",
"         RE",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         CS",
"        </p>",
"        <p>",
"         SM",
"        </p>",
"        <p>",
"         RE",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         CS",
"        </p>",
"        <p>",
"         SM",
"        </p>",
"        <p>",
"         RE",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        C, H chain only",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S if no CS",
"       </td>",
"       <td>",
"        S if no CS",
"       </td>",
"       <td>",
"        S if no CS",
"       </td>",
"       <td>",
"        S if no CS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgD",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note that the nomenclature of development stages varies among authors. A mature B cell may give rise to both memory cells and to plasma cells, but a single cell cannot be both. Memory cells may be activated, and susequently divide and give rise either to new memory cells or plasma cells.",
"     <br>",
"      S: surface expression; GL: germline; D: diversity; J: joining; H: lg heavy chain; V: variable; RE: receptor editing; CS: class-switching; SM: somatic mutation; C: cytoplasmic expression.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102 (no table number).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40076=[""].join("\n");
var outline_f39_8_40076=null;
var title_f39_8_40077="Developmental screening glossary";
var content_f39_8_40077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glossary of terms related to developmental-behavioral screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental delay",
"       </td>",
"       <td>",
"        Weakness in one or more domains of development; most often refers to performance below the 25th percentile or the 16th percentile",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Developmental disability*",
"       </td>",
"       <td>",
"        Significant discrepancy between intellectual ability and other skills (eg, language, academics, self-help, etc) or overall deficits below the 5th percentile",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Psychosocial risk",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Parents with less than a high school education, being a single parent, being unemployed, parental mental health problems (of which depression is particularly common), housing/food instability, &ge;3 children in the home, limited facility with English, limited literacy in any language, being among an ethnic minority, and most importantly problematic parenting style",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Developmental screening",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        The use of brief validated measures to sort children who probably have developmental problems from those who probably do not",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Broad-band screening tools",
"       </td>",
"       <td class=\"sublist_other\">",
"        Measures that detect probable problems in most or all developmental and or behavioral domains (eg, language, motor, cognition, self-help)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Narrow-band screening tools",
"       </td>",
"       <td class=\"sublist_other\">",
"        Measures that focus on a single condition (eg, autism spectrum disorder or ADHD) or on a single domain (eg, gross motor). In the case of mental health screening, about 50 percent of children with mental health problems have, as the root cause, undiagnosed developmental problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Administration methods for screening tools",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Parents' concerns: Parents' comments about their child-rearing worries, in their own words.",
"        </p>",
"        <p>",
"         Parent report: Parents are presented with descriptions of milestone-type tasks that most children of the same age can perform. Parents are shown multiple-choice answer options, such as \"rarely, sometimes, most of the time.\"",
"        </p>",
"        <p>",
"         Hands-on/direct elicitation: A child is tested by an examiner or provider and thus requested to demonstrate the skills he/she possesses.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Developmental surveillance",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         A process that involves:",
"        </p>",
"        <ol>",
"         <li>",
"          Eliciting and addressing parents' concerns at every well-visit",
"         </li>",
"         <li>",
"          Monitoring milestones in development, behavior, and mental health at every well-visit",
"         </li>",
"         <li>",
"          Observing the child (and family)",
"         </li>",
"         <li>",
"          Maintaining a family and child medical history",
"         </li>",
"         <li>",
"          Identifying (and continuing to look for) psychosocial risk and protective factors",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diagnostic testing (\"criterion battery\" or \"gold standard\" evaluation)",
"       </td>",
"       <td>",
"        <p>",
"         Detailed investigation of suspected or obvious developmental delay, the purpose of which is to make (or rule out) a diagnosis. Potential outcomes include:",
"        </p>",
"        <ol>",
"         <li>",
"          Definitive diagnosis of a developmental-mental health disability and comprehensive interdisciplinary plan of remediation",
"         </li>",
"         <li>",
"          Realization that there is no significant problem",
"         </li>",
"         <li>",
"          Decision that additional observation and reevaluation is necessary",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Early Intervention (EI)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Intervention program funded under the IDEA for young children (in most states 0 to 3 years) that provides needed therapies (eg, speech/language, physical therapy, occupational therapy, early educational intervention) according to an individualized plan; services are provided only after testing to determine whether the child meets the eligibility requirements of his or her state.",
"        </p>",
"        <p>",
"         Although \"EI\" refers to IDEA services, providers should think broadly about the many options for early intervention. When children do not qualify for EI, clinicians should consider referrals to Head Start, parent training, quality day care/preschool, social services, etc.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Public school special education (SE)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Intervention program for older children (in most states &gt;3 years) that provides needed therapies, regular education consultation, and other services with an emphasis on educating children in the least restrictive environment (mainstreaming children in regular educational settings as much as possible); includes an individual plan for learning with goals, objectives, teaching materials, and expected attainment dates",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: attention deficit hyperactivity disorder; IDEA: Individuals with Disabilities Education Act.",
"     <br>",
"      * Developmental disability is a term most often used by the public schools.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The presence of &ge;4 psychosocial risk factors increases risk for developmental delays.",
"       <br>",
"        &Delta; Note that surveillance and screening can involve the same measures. Some tools enable surveillance and screening to be accomplished simultaneously.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Established by the Individuals with Disabilities Education Act (IDEA), which mandates free and appropriate services for children with special needs beginning at birth and continuing to 22 years of age.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Council on Children With Disabilities, Section on Developmental Behavioral Pediatrics, Bright Futures Steering Committee, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics 2006; 118:405-20.",
"       </li>",
"       <li>",
"        Glascoe FP.",
"        <a href=\"file://www.pedstest.com\" target=\"_blank\">",
"         www.pedstest.com",
"        </a>",
"        . Nolensville, TN: PEDStest.com, 2011.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40077=[""].join("\n");
var outline_f39_8_40077=null;
var title_f39_8_40078="Intra TM squamous pearl";
var content_f39_8_40078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intratympanic inclusion cyst (squamous pearl) without middle ear extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgASADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2yBwCMHPvU7TZGBWPDcdMn6n1q/A4kAPavAhJtHrShZjnOSeTTkX5eeBnmnhACuTgVJ5TMh2dPWtErk3ItyIhzUHnKTkY44pl4kkY2g/lVaLO4AkHis5PoaxjfUtA5OexpxbAzggCoCCAMdamTIX5jkCgGiM3Jx3xUXmu5wKdN90BF5JpsKnGSOM0tRpIdKdowAM96pSBmJAPtV5o3Ljk4P6VLBaYOT1NNU22PnUUUoLHcMv07Cri2UY/hxWlHCqAnHtT0QF+elbKiYyrMynswQdq4FRS2vOAOBW/5II+WoZbcdMe9P2KJVZmOtuAen/1qkMRRByeec1qRWwPb8aV4VVeRTVKwnUuYv2dmOckj0NSrbgDnBPpVh1w2R0qWKMtS9ncftGZc9llc4ziq/2cAgEcV0EsQAxjpWXdLhzk9e1TKmVGo2QmKPaBiqr2vmc4yPTFWCCAO5rZ022DxguBSVJMp1HHU5a500BSxXBrNkjWInavT1rt9ThCoRjOe9YN7bJ5RwMEDNc1ely6nRRr33OTvpMxnHWufuWyxz0rb1F1R2UNyazHt94LYJFeRUd3Y9yg1FXZmqmSCDyetTpCrdXHvTpLZwTgHmqsgkiyT0rPlaOxS5tmW3jRBkevenxxRSKSrjdWU9y2DuPFNS5YNxwKm1x8krG5BO0J+XoO9W49amjOC5wK51bw8A9Caes6scHqa2p1XDYxnh1L4kdtp3iLDqGf9a09Tvhe2To2GRxjBrztMFgUYcelamm35WQRythfeu+njGjz6uBjfmid7A3mcE4HrWvAwRNoPHb1NYtsApzngDkVrWvzKD+VdFK55VVItocyAE1fMgjiAyAKzuAVxTbiTapPPHSuqMrROZx5mMv7lckDGcVnwtul3OcLjpTnRn+Zj1zionwuMda5ZNtnTFJKxbDbWJJBzxV2Ndw571k27qSC2T6YrZtyHXB4IraDuZVNBDbhjwOT+VTJbADnFSJgHGKcckjnit1FGLkx6QqqjC9avW1vGMMwFUd+BxUqSNjtiuinYxlctTwow+QYJ6U2K0AHJ4NNEjEHJp32na3NbWRnqWFjVAOBmoJlB7AE0w3Yc4HX2oJyvB59absCuACqvHbvUNweMZHPFNkl+bANJIDsBJ5rNlFVhgk+lRiXZnkZ/lSTluecZ9apzEjnnJrGWhotS7JMCue9ULnMjLtNRCV2YA9zxW1Z2okQEjNRbmLvyGOF2Dnt2q3b6iIlCsfmp+qwmEHggVztwPmJRj7e9ZyfJuaRXObN3qKyHGawdZvtqMFbr6U0k9D1rM1KBnXg5J4FcOJqto7MPSimcrq93vuRtOee1amnjzIlLdB2qg1gRcbiM1qQQhYwBnpXk0U3Jtns1ZR5EojJlXefT1qlc23mDpWk0OeWGB0ApsseVAUHPqa63T0MoVLPQ5a7tirdCRVN0ZWxj8K6eWHJ+lUJbTcxwKwnSe6O+niE9zCJKsKsrIuFDdTV+SxY8leKpT2pX7o5rNxa3N1OMh058goY24PapIpgwH94d/WquOPm/M1F5mxsmhaBy3R7XHHufltoJq8km1QoABpVgUA/nVdomjLkksztuJ9B6CvcUXHY+PclItCXBYLzxTZCzqd2BiiCIsSfWrAiJyB0q1dkNpGbO5yB6dhVchn6kE1qS2wKkiq6x7RgAE+melTyFqaIrWPbwxFa1u3TH/66zo42Y475rUt4SANvpWsImVSRYHX3xRyOM8mnKuBjtUgjJIHT1roUWc7YkcZbG4gfWpxHxj+VJtwRinA4ye3rWsUZtjiPl4qncggVeH3eTx61BMoPXpVtEplaHr74qy5YLx0qFMKTx+dP35XnrUIbZGkZdyferaw5wDz9KhXJ6cVZV9ijB/GtEiWyvcWqgHPNZdxGBkAVpzTDnkn3rNuZQBnv2rOaRUWykibZtzdK6PTZAY8VgINzfWug0xNsQ4yammi5u5T8Qc25IFce/Dkkn2rttdwIG71x4iDyE84FYYhXN6ErIquOT2HpULoHBxVq4jKg46VXJwOa4JwudcZmbPAFwFH1xUaRMjc/hWgw3t0x6mleMBMH65IrFU7HSquhmSEmTB9eKS4UrH05PatC1tvPuQB0p+twLHtUDmr5ClU1sc065JIPeqwDh/bNaSxYLE9+arTMEGQBmsXpudkJdCC4n2LhlqkzLI47CrVxIrDPesiYsJMr2rKbOqkrkl7BlMqKzHiZh7VrQThvlY8elJcQA5aLr6Cs3C+p0Qm46M97jtgTz0NPNmoI45qeJSAM+tXI4+ck19SqSaPhXOxliAJ2wKaY+pAI5rVaMc5H4VEIA59vWpdEXtDOaHNJFpyF2ZV2l+SfX3rXFuoGMVJEgB6D2xVxooTq2M02CoBxz/OpYYMDkc1pSKMkVDHHlt1aKkkQ6jZC0YAB60wDH19auuOnXiq+0FiabjYlSuNVSTk9KVxgc96dnaMHr3pkjj1pBcjcEgcn86jfPFNeXb2qBpwOnX+VS2NIe+TnkUgRsjJ+tNicZGTwKmV/MOOPYUJDbFB+YDsOtOkfC8HGKlSJVPzHJqC7xsOKb0JWpQml4PWs29lORUs0u0lSapzkMPlAzWEpXZvFF/TUM8gGOM11dtGY4sDNc/oC7QueSa6N32pkela09jKb1sYniSX91tHU1h2Me4fN+NaOuuJZAM0ywgDDPQCsqurNoaRM+7gyxCjjtVWKweVydpwK6Ce2y4CjipoEWCI5xmsZUky1Va2OTubfySB0qB0PlkseMVqX7rLcMQAQKzLqQbSF61zTjbQ64SbKkU3kuWU4Iou5zcOC/pUWMHcw/wDr1E5y3B5HeovY6EtbkVwu0MBisecMzZPStmX5kOeAaoXKqufpXPM7KUrGTOAvAyazLhjhh3rWm4HbNZ1zHhc9655rU9CkzEaaRJeM4/nWrZ3DFlxznqKoyIN3POTSqTCQVPTk1mpWOySUkfVzxgEALxTNpBHp6Vccbj/s/pTdgyCRn3r7VxR+bcxBs3AZ4FJHsKsE5AO04HQ1YIAx6U5FBHoBQoiuV9uD0wKdGCT3qVkBxTYI3CYZs4J+b1oSsF7jWHWmgbV4yfWnOmw9Mc0xnCjrSbCwkh4qBgPxpkz8Zzmq3nANgVnJotJlliCvrzVaUgAljzTjIDyCM01o8qWJOAM5rPmLUbmfcSHjAqoznOckc5qWdxn29qrY3MayctTRLQswFpGCjpW9aQCKLLjnFZeloF+Y9RWrJNhfpW0LWMpkVxKEye5NZ13NkHceKW4ZpWJUcCs69bahGecVNRlQiZ11NmU4PGetMEgLgdQap3DndwRVeO4xKozjFcrndnWoaHdaIQfQVszuFRs56Vzvh+cFOPz9a0dQudsRAYV0Rlocso+8YmpybrkYPerFrOFjwOtUJQryEnk+tPgbBB/KsXO7NuXQ2oyxwzcVkapqIVmRDyOtWLi8CW5wea5O7lZ5GLHgnNKc7ajpU7s0rcGZ8BhnqaivrcRcnv0qnbXLRsSD0p11dPctkfdHSuaTudUYtMoTNzgHv0pqrkknpSlCZOnGallATAHcVizqRC4G3GODWbd8k4q7NJjOKzrhs5yOKymkdFIzbjBkwO1U7pxwvtVqRsBiec1QmwWHNc0z0qS1KFydh+Xrmq7MzZz1qzMQW5phKEcc8Vi2dsT66XkZzxTTlSeM0z7oO05J/SnqoIBPUV9wkfmjGtnOKkX7pGO/pTJMg5zxToiNoPWmIlVB0I6U44XA9qgeXDdeKhlu+w6VLZSQ67cAgGs+aTvnFFxcAt1wKz5rjJ9vrXPKZqojp5fSqTzH070SSHPB4xVZ37k1zymaqJMLhkYZPFPlvJZVKZCr3A71Qd8EmljY4z2rPnL5RxJ3YA9qkWJgvTmo0dvMOR06VZEgKdqaYmMW5MIxnpzVi3uDMeTlBWVcuN2Bzz2qWByi5zjHarU7aCcNLmzNIqxkjgVzup3AIO3rmp7y6ZkwDxWVKC7cZqZz0Kpw1uZ0zkk56mq4x5uRk9qutES/PeljtsH5fzrlZ2JpGrpMrQxZU+3Pao9SvnZwu7pzii2yqBcA1FJblnyQSTV87SMlFXuLA7uAcnJq0suzJJ6Diksrfbj2p0yLzkZPSpb6hpexRlnJJL/dJqhcfM2c8elXLoAkfniqHUnNZuXc3hEjRWOTmrUXJAxzjFRdB2OKngYKoLY9c1N7mjJWhVIc8etZVwx3ZPNaEs/mY549BVG7G05pPQun5mfK5OKoXTgZAP1q1duNp6VkGUyHBPGeMVjLVWO2nHqNmIIIqhMMKTmr0oIU/WqFxwpGcn1rmqHoUTNmBYnJNAAWMHvSuBjcaqlyO/FZeR3JH2KOvA7/AKU5cAc0SZDc1A7nBr7h6H5ja5JMQQcdKjdwqHJ9+KpTXSxnLH2xVK61BcHB69qzc0i1BmhcXSqMZ6Vnz3YAOG9uKzZrln681SnnPQE4Fcs619Ebxpl6e7HTcKqvcd8/jWbJL83XJqJ5z1JwBWDmaqmazXA25HJ9KrvcHJArPE5bp0pNzMTyfSsnK5ooWLjSgkAH8KUyYHNVMc5zS7thO489qSZTiWkdsnOQPWnrPgkA/hVUMNuAT9PegkjleSe9NSJaJmJb5VJGe47U9FEcKxqS2Bjk5Jotoi2B+tSTRlccc+goT1EyufmOBUboNwGfxFWI4ixJBwKlS2JIxTd2K6RTgsy4JA74qxLZ7Iv85rXtIPLj5p7wbyO9NQuJzMiyt8YyKluoduNq+1ay2uD9KSS3JHTmh0xc+pl2qnfyMior2Ng+5enpWxHAFIOBn6VWu4x0z2qWtCoy1OeuUyd2AOKyrh9uf85rfv0zHtAx71zl6Ah5rknLlO6irjVlPQnimzTnHt6VmyXGH2g/LT0YyDB4FY+1OtUrastJcHAye/6VJMd4z2qptAIqVmC7iz8EDaPSq5tA5ddDHvS+Txx2qtApzyKvXABY8YA9az57hVwAfrUvsdcFfRCXTgAgc1l3LbRyc8VNJMZCeOKrTDIyetYT7ndRjYpzMAPes2abaTnI9BVu6Pp1FUZAGOSQRis4I6z7TcYHJyRVS4fA44qad9ozisi/utiMS3QV9lUkkj80hG7M/U5hk5PBrGklZiepp2oXYZuaqwTqz815lSpqejCnZXLYZiPaoZ2ABFPkkAXPaqUzM2az5roahqQzSYJJAqsZCzjrTZidwA6k8k9hTASp7YrOUrm0Yk6n5s9qlD89RVEtg5JJHap1Y4HqeaE9AcSwZcFh3qRfmYHjpVdQDk45qeNsEAindEtEyqepXrU0EeQS/foKhaTHrU1vJnG4Z9vWmmZtMvxFRhAeRUrR7hz3pkEe4524Jq6sRAXOapK+pmyvDABxjrzViOGrSx5PtUqxgH6VtGJm5ESJwFqWJMHpj2qaNO+amijyc8itVFmbZCVJAwKa0JOTV9Yc9j+VTGEdMY9q2VK5DnYyWi46dKz7qFsZxXTGEFKp3NqGXp+FZ1KGmhcKmpwmqSGMHHXrXDapdtvbJ716TrunHy3cDmvJ9byt4yAHg14WJvB6nu4FRmReaeWY89hVqCc5VVyR3NZIV+f61bhmER965oO56U4I0mnIbngCmPOVOD26mqgn3EkkVWups98VspWM1Tux2oXoUHB5rG80yE88detR3cpZiAagV9g5xQ5WO2nT5UXPMwevNNdwQcnkcCqIlJcZ/Sns/wA2SeKxmjqhEr3hUKQTzmqMbbn+Y4FTXTbjj86py84C/jVQWhtufYNxfoV5bHvWDqGoRlXBPFV5piRySf6VQlgaXOAdo7+te5VxFz4OlQS3Mue8LzsCeKuWx3Lk8DFUp7ExSb6fFKVyOwrz5Tdz0XBNe6WprjGc9jTDcqq8tyazrufGcfWs17kqckjFL2ttAWH5jYnmBJ5yAcmoFlySO1Y8l0QetLBdMWIxge5qXVWxosO0jbiTzD6AVOihcd8cVnw3HJANWUn6BhVKdzGUGW4nAbkg8/lUyyZBx1/pVNmUEN27VJE24YzVKRm4dSzksD3ParmnxMWG7ue9R28YOPyrXsYB8vGKqLuzGWiNGzgBA7kd6vpB61HbYQYxkVbUjgEdq76cUcU2RGMLjjrUqRE8461PGnGcfnU6oAe1dUaZhKdiCKHbUscYHbmpQRxjFOA4HHWtowsZuVxwG0KSB9KAMjINLt44p6gAc4OOeKuxFyM/0phXgd6kYHOccdKUgY/rQ0NMyNRtVkjZcZzXjvjTTRZXjysuFxkNnqfpXuUqhgeK8++I2nrLp8jgcgZzXk4+gmuY9TLq7jUS7nj8l2uOMAZqIS7s465qk4AkIPGD3pTJg8V4Ctex9b7NWuWTMex46USsSoPUmq6naeTk96tGSNYs55rVXtoKyTM6Vckk8CqrrnpU87ZJOSBniqzuAcL1pM6IXGZwx9aZIW3HcecUqt8xLde1LhSpbr71DOhbFOVtmciqjy4YDNWrrH8JzzWZdKSuRnNb00maU4ps+lJLoYIHNTwXyiIBxgCuSTUCR6YFSrfEjB6kflW/tUtGfKvCs6W6uEdcAVS8pXDNnj371mRSs7AMcA1ohgI8jnsKzck9g9m4aGVqKbeM47k1lE59627+FpI9xWsSSN0ODx61hNdTrpaoYy55wOKjjb5xzxUjnGAKrhiG6YrJvobqNzWsvVutWlYnLDp71TsiSo75rSRVOMD/AOtWkZnJUjZhESWwx4/rVxGO4HsOKrrGM5AyBV61j8w4bIHatYyZzzNSwDMq/KOfzrdtIyQMrjFU9Mt8Yx+dbUKrynG4ds9K76MbnmVpak0CBR061biQ5yelJBECAT26VaCYxkfhXqUqdjhnINhaMqDtJGARzinoMDBOecfWpEBIzxTwnpiulI52xsaEcnA9KeBz0pwHJz0pB+lUiQ25PtSgGjPHPf3pQRQAjDqabj604nI46VHznpj60MY1+cj1rB8SWyzWMqsM8Vvk4HNZWsAG2k9SK48UrwZ0UHaaPmPxDF9n1OZB2Y1lAuxGM5rpPGKIusz8jr2rEyqjCDmvmZL3nY+8pSvTTEjRy3JwKsmNVXls1R81wTnvVhASg+tXrYLakdwvpVKTg4Aq9cMqKdxHHb1rMlcMc5/AVLWpvTHod2eKa6grkvyf4ewpU24GMj096SXAzjk1mbJXKp2ljnqagZc54zUrKd3zHnP5U9lZQBjg1qnY1irHoTK+7jNPErRn5s5qxaYPD9+cUXcabRWXNZHkpq9mLb3gL43ZArbtrxWwAeK5yKADocjrTt7x/KDgdauM0zOpSjLY7CV42jUAg+uKxr6JGBI61nJfOCASQKm+1iQ4zxjFEmYxoygyBYz1I5qGSEgls4q9vU4IPSop2BUYIJ9Kxn3N4t3IbaRkP+zWhBJvwG5Gc8VlhwrfSrFvMQ2c4qFJ31CpTujpLbBjXIODWpYQ5cDvWBaXQYAc+nFbdjdKi5ZufWumnK7PMrQaOlsm2KQDWrZxmRsgdevHWufsXMzqMjBOeK7OxhCxLXuYSHMrs8bEPlHxR7AABUyDdknOafs/L1pcc5Ar00jgbuCL1HOPQ1JQvAoPSrIE60084WgHHvTc4bpimA5hkdcGkIwaTqWOfpQTkjjgUgHMTj3NNPvR2Gc8Uwtyc5/wqWykhJDWJr04is5GJ4ArWlcAGuS8WSl7KVVPJB6V5uOrqENTswtPmmjwnxLcLPq08mcjcayfMVRxVjVXSKeZH+9u61miZFyTya8L4nc+4pxtFImEm9z6Cpy+EAGaz0ly3ynqanZvkquWxVtSpeSb3ODzVdM54NJcuNxqSzAIHHNJ6I6IlmIfLnH4mq87gMOc/WrbNtXauM1lz5LAfnWcFdmqQxyWk3K3Q8UrztjbnJ9amxswWHAqvdEOSVXrWqs2bQVz1Ztqtx1AqKaQkYxnjrUF0zI/XFOT5gAPxrkbueQoW1ZLDIQCW/WlJD/SnmIbQfSomyrYAqb21Fo3oHlg9OtQiFo1O5ixJ61ZVgo5oJD4wCQKpT7ju0UY53xlSCucZFPN0COetaCW8ciY449BxVO6sRuygqm9BxlBuzK/nA8E9asRsxxgYrPdWiPzDGO9aFkwOC/So6mk42V0aNrFIANp61q2+cohYBnPygnr9KzVv440AGKt2OpweahkUEr909x64rek1c86tGbV0jvfDdo5YEjOK7a3XagFcv4XvoJogFIyRXVxEFRX0mDSUdD5bFtuepMD8opaaOTilPUV3JnExcAHOOelIx9OlKT60x6dxCBsk9eMZ4pF96B0680ZyfSlcdhT9ehzSZ9z7UmQKazCk2NISSQIPmOM9KY8gx6f1qG4ILZz0rH1jVorSJmdwAB3NctbERgjanScnZEuralHaxM8jAACvOfEfi2zWCX96GPQAd65nxr4va/eSCBz5Y4yO9edzyu5bcxJJ7mvAxcvbaM+mwOXcqUpj9UvBc3byN1Y5xWY7ksSOlOlzz61ETgc9qiEbI9+Ksi7ZkDLMfwqWW4Rsoh/KshpXyQDUkDfMM8k1pbqLlvqW1QM2TVuFFQgHAJ7UyAHIOOKfI4QEgcnrXPN3djVIJTxtHJqqsTFzk+9MuLkpgH+KrNu0bwMxOT25pWcVc1sNkw0ZAxkdxVOJN+VByanLtllUcYqj5rI+V5zWsEzaKPSZ3LY7n19KtWJAABH50jwho/lGCe9Os7Zkj2lizep7VyN6njykrWLbOufl69qgIDnr3qGVJAeGNIjFFwc1mhKNtUSFMEg01gVXjPWopLgZGOMUecHHU8UN22LUX1JY7ggYqQ3Qxye1UGyc1VJkZ+mAKHOxSpJ6k1624ZH5VUW6ZDjFTFZGXJzVeSLaCcUm2bKyVhJ71s8dqZFeyK24moGTg5/Oqs8u0YzgUJX2Jk+x2vhXxS9jeoryfKT3PSvdND1iK+tkZXGSPWvkoysrbgTmus8K+M7nTJ0WRyYx+levg8RKl7rPFzDLlXXPBan1Erqw5PHWpQwPauK8M+KbbUrdWEgzXVR3KMMg17lPERkj5WpQlB2aLhIB96bnOMmq5mGDtIzjjNNMw6ZOO9auqjPkZY3euPyqNnHFVGuVGctiszUNXhgUl5AMeprnqYqMeprCjKWxsNMo5J6VTutRjiQsWAx1rh9Y8bWtsjBZAzDsK8617xrdXu9ICUQ981wVcf0R6VDLJ1NWej+JfG9rYq6xuHk6YFeSeJPFN7qkrAyFY/7orHllaY5dyWPqaqSMAeDXBOs5nu4bA06PmyN8nqaryuF78mi4fpg4qpI/wA5BPNZpN6no3sOJ4JqvI/PoKWSTsKjEbOcYyTWyVtwv2EVdzZrRtYCRnGBTbO2OeR3rbgiCx4x0PesatW2iNYkJXYgwB7+9U5nz2q1PINxwc1CihjlhxWMX1ZaZVntRJFvLZ4plnbyBsf8swetXJEO0gdDwKcY2hiALfe6Vrzux0J9CndDDfKetZ0m4o3GBWhMwCEZ+Y1ny5ZWA4X1rWmax0Pa0gDKoxya0Y7FfL6darRYyvtV5ZtmckVxo+Ym5dClcWIXJrJu42QnpjpWzc3QySTWVeXCmok7G1Lm6mW8YY4xz/Km+VjAU9ashRIepGauQWinkdu9ZWb3Op1OVFKKBi3PSpxbRqwJ61YkURnAxVaSVRuLtWqh1MXUb2J3jiEeMc1lXiqM8DntUkl4CvB6Gsm7vCSTn5v5U3FbFwjIZccKax7g7nOOnarU8pkAUGq5jJHPeqhFI39Sk+QeajUkHjtzVmaPaTjFRBMct0roWgrdTW0fW7rTZA0UjADtmvR9D+JBCItySK8ckl54/CnJLggg5rWM5ROWvhKVX4lqfRMfxBsWiBMmDVa5+IdooIWTI9q8EW4OeWIH1pfP5+8abrSZyLKqO56zqvxDZ0It85PvXF6r4mv75zvlIT0zXPLKOvWmSzc5HWsbu51U8JThsi0107k7mYk9yajMpz1z7VRM3P8AOnGXt60We5vbsWWl+brimyyAD5RgVXVgW6mnNyMCjlQ0QyuScnn0qvL096skHPH50q27ORxxmtI6FKJVihMjdK07K0J2hlIq/Y6a2QQM+vtWvHbRxoDxkVjOq3ohxtErQ2Yhj3ECq1zKMbVP5VdlkaUFF5Hasq6t5IpFYgnnmskru5pAYIH4JBxnrUzK2wKBknuKsg+Zbk4IOKYzBI/vYYU2axK8wI2DHIqvdyLwQc4FLfXGMFieeMCsRrsEsueDWlOm5amsU2WbhhtyuBVGR8Ljt296ZJNuGAelQSOTwTXXCnY2irHtdnqiOuNwzU0l3xyeK4dZGibKHnNXRev/ABN0ryG5LY8Z0oXua19ekjCH61ChklY5PNUUlVhzyT+lTxXAQ5zntUuTe5rZRWhr2yhACx6VZ+0bOhrEN6eQDgUxr7CnLVSkZOm5PU17m5XBPU+9Yl1cnJ5684qncX+7Pzc1nzXO5h19auPM9C4wjFl6S4OOTVJ5dxqBpSze1LvGM96tRsaX10JkB9KJG4ximLKQD0NM8wNIOcnrW8Y9RPcaFLvjp9aivSE+UEcCnTzjHycVlzyMSSTWqhfVgmDMQSTTBLk4zg1BLIe/6VEJMYOMenvWqgLYuGXgfpSrLk8dT61Rd8v14qWJgASTTcLIh6GiuduaRiSoNVvtH8I6U6OQsD6Vk4tC1AsQ3NOGWbjNIq739qv20AUbjQ2kJIZDEepqwsJJwRxU0UZkbgYHatazsi4AC55rByHexlRWRfGMj6Vq2enhMF1GD0Yf1rWhs0hQ5HOKZLKFjwOAKlyewubm2GvIsUW1ABVMFpWCgEntilVXkb5gQCa1rKCOMF2OFA49TStfQptQRDZWTYLEcitCPSWu49vkljXQ+H9MhuovMdiNx4UV1tzp9jo1mJZ3w+Mge9dEKKtdnnVsbyy5Vued61pX9maPEGgSMnlj1Jrzi/lwzEHABrvPFniCO5WRXbcBkKOwrzW8cuGOcDOazteR6mEU1C89ytPNvYknt0rJb5nJzke9WZG2KfX3qqSMdf0rtpxtsehDRCucLg9fSiFDLIMcjuaaqs57n2rWsLQrt4zTnNQQ5TsXmuiBgE4qRLliMbuvrVAD3yR+NSAYx0Ga4nBHG4Gkl2UPynIqZb3Ix0rKUEA+ntTgCazdKLItY0jckLuDdahkumbjPftVXaduTQFJIPT2oUEiddybex6mlUY+8eTTIw3U1YSEEfKOTSbSJtciKbu3FSQxgN8/SpxEF4xVaYsCc0RldlpWC7lVRhO9UxLhc96HUtyTzUUg+XFbxsK9thZpc9RxiqUjjB4p0uQP6VA5OMY+preKE2QSvzx061GWLMNp/E06TgD1PanWluZJVyOK20SuJsQQOybjwKnSGQIWbhR0rTksnjgDuNq44BqhcGSTgkhR0ArONTm2JZXQ1btwWz1ApsNuSowCK07W2OQAKmpNDUR1tASQT0rWhsnIGF7VPptkGwWrdhiVBzjFck53JbsULKx28twK1YxHAgI61E8yhSBjNRNHLK6heajVkvXcdNI0rbV6n0qxYaXJczqHyAau2unC3Cyzc56102lRI7I2VVK1hBt3OarX5F7pnJ4dMiqsMJfHfFPt/CV5I+6RdkY65ruLHVrK2jcSyLGi8Z7muY8WeNVA8jTWwD/Ga6nShBXZw06+Iqy5YIoT3Mujny8qgHT1rkfEviee5dt8rORwBniqGr647F2mYu3qTXJXF20jv/tdzWHM2rLY9ihhVF801qSyTyXEvztkZqO72qOvbmhBsUEdetVZiS2CevWkldnbdIzLsl5DgcdKjii3DGOvStAweYcKuSTV+x07PUV0OsoRK9qktCHTbHkcV0ljY4IJFPs7Tao+Wtm1iIxuH0rilNzdzGdWxwEbqqnPBPSoJI2V9ynJ9PSowJGyx+6alJYKDyBXTazO1wsyzZsygb/mz0q0GwxO3NULSVdxJbpxVxG/X9axmtTnnB3LQw3UCpY4FPp71XQHjHbmrEWQeMn/ABrCWmxnYnSEbcgDFOUbPujj+dRrI3Snq/PSsnfqKyGSbmxjr6VCYGLHJ56VfXGzI696QxAjqKFOwrXMqS3Pbmq7RYAJ9a3Gg3A4/AVVms/n4OR7VtCqJowZoWZzjp61GLbJAbpW6LU5A29Ka0AJxt6Vsq1iUjF+zLkBR+NTRQFWAQfN61sRWIZSf5VaisVBB2ik8Qh8plrBNMP3pJHpSiwOeRxWyIgpHbtUwVGbrwKydZsfKZ8NgmwYXoavW9mqKC2KsblVQqD6U/y2JGc8Vk5sWiHKyxrwelRGeSR9qA81YFo7OCQQMd6sxhICMYBFNSfQzukJZ2UkjAy/KK6fTdNiADbh6mubW7w/JO3P51cXWhBlUHH1raCjuzmqxnLY3ruNZHChW8teSazbjWEtG/dRfKvrWfdeKJTAYkVEB43VgXupKytuO5qpzS+EKWGk/jRc1bWbifJzgGuZub6TdlpNzVHdXTzcE4HYVnMdsuCSSe5qleW53wjGCskLd3bTPwM81XDZYnoakmYDoMZqAq5wEFaxSsHNqW45OPU06C1knk4HFWdO02R9pYHFdRY6YqhSVrKUrO0RSlZamXZaVhV4/GtGK0VDgCtcQhQcAADoKb5OSSelZcre5h7Ujt4ACKvxxDPHOaRY8Y7VMDlsLxWsYmE5tnjwuAFB/MelAmV1O7gnjNUieMc4qRDtXJOSegrrcEfSuKLMaqp9fSr9uhJHOazbY7pBk/KO5rXtS2VAAAHf1rCroc1VWLSQPxn6Gr8QVQF71CA6qM4FKVJ5U9K4ZPmOZ2H7Q7HaCKUR4yV704oQAQeaAdpBGSajXoS4jSGUZbqegpcsuP1qUtnBx83rUyR+ZGSOtArWKyOwBJp4kGMAdKkaJACD1qNIC+cdBzikDbGPMAvTJPeq7zjsuSK0bezEnb65pyWEby7VqtF0J5rFKGYleOpqbzHxz+Vblpo0aAs5GBxmppNOhUEhePWqt2IdaNzmtsrsDgknoPSr1pYySSAYrTlEKRlYlGR3qWzeOPlmAala+hMqrtohZNKFsgeRhuPb0ojjiVS5xkdKZf3Sn+I/jWY92ztgNgUOyIjGUldly6uyc4PAqhLIxPB7dKhnnVUKg89ap/avl68mlds2jFRLshPBkPTmqM90c8cDpTJrpnXAPy9M1nTynHXkVpCLe5V10LbzFgcniqkkhY8n5aryTE8Co1MkjgKDW6p9WO7ZI7hfqf0qFlLycDPtWpZ6NcXLhnUge9dJYaJDasDINzY70+dLYlyUdzmLPR57rDbSBnuK3LXQViUbhknmuljMcSBVAH0FNnbj5e1Q25bmDrPZIoxwJAFRR8xrRiQBTx+NV4Yju3sOfSrBbaMdW9qaMpyuMbIOAPqfWgnJH9KTPPqaA6jG40uaxJIrYySeKaJwc4qtPLuZgp46cUgYBffpWilYmx//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intratympanic inclusion cyst (squamous pearl) without middle ear extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40078=[""].join("\n");
var outline_f39_8_40078=null;
var title_f39_8_40079="CMAP postexercise facilitat";
var content_f39_8_40079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Compound muscle action potential postexercise facilitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 507px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     A)",
"    </strong>",
"    Exercise testing in Lambert-Eaton myasthenic syndrome, with the median nerve stimulated supramaximally at the wrist and the abductor pollicis brevis muscle recorded. Top: Baseline. Bottom: Immediately after 10 seconds of maximal voluntary exercise. Note marked increase in compound muscle action potential amplitude (postexercise facilitation). Preexercise and postexercise testing, looking for an increment, always is better tolerated by patients than is 50-Hz repetitive nerve stimulation.",
"    <strong>",
"     B)",
"    </strong>",
"    Slow (3 Hz) repetitive nerve stimulation in LEMS, before and after brief exercise. In both situations, there is a prominent decrement. However, after brief exercise, the baseline compound muscle action potential (CMAP) is significantly larger compared with the CMAP before exercise. In this case, the CMAP increment after brief exercise was 2000 percent.",
"    <div class=\"footnotes\">",
"     CMAP: compound muscle action potential.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and Neuromuscular Disorders, 2nd ed, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_8_40079=[""].join("\n");
var outline_f39_8_40079=null;
